

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 02	CA/Caplus enhanced with pre-1907 records from <i>Chemisches Zentralblatt</i>
NEWS 3	OCT 19	BEILSTEIN updated with new compounds
NEWS 4	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 5	NOV 19	WPIX enhanced with XML display format
NEWS 6	NOV 30	ICSD reloaded with enhancements
NEWS 7	DEC 04	LINPADOCDB now available on STN
NEWS 8	DEC 14	BEILSTEIN pricing structure to change
NEWS 9	DEC 17	USPATOLD added to additional database clusters
NEWS 10	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 11	DEC 17	DGENE now includes more than 10 million sequences
NEWS 12	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 13	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 14	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS 15	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 16	JAN 02	STN pricing information for 2008 now available
NEWS 17	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 18	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 19	JAN 28	MARPAT searching enhanced
NEWS 20	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 21	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 22	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 23	FEB 08	STN Express, Version 8.3, now available
NEWS 24	FEB 20	PCI now available as a replacement to DPCI
NEWS 25	FEB 25	IFIRE reloads with enhancements
NEWS 26	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 27	FEB 29	WPINDEX/WPIIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:10:22 ON 24 MAR 2008

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 15:11:59 ON 24 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAR 2008 HIGHEST RN 1009738-20-8
DICTIONARY FILE UPDATES: 23 MAR 2008 HIGHEST RN 1009738-20-8

New CAS Information Use Policies. enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10522004\10522004c.str



chain nodes :

ring nodes :

Ring modes .

chain bonds :
 2-19 3-18 7-11 11-12 18-24 19-20 20-21 24-25

```

ring bonds :
1-2   1-6   2-3   3-4   4-5   5-6   5-7   6-10   7-8   8-9   9-10   12-13   12-17   13-14   14-15
15-16   16-17
exact/norm bonds :
2-19   3-18   7-11   11-12   20-21
exact bonds :
18-24   19-20   24-25
normalized bonds :
1-2   1-6   2-3   3-4   4-5   5-6   5-7   6-10   7-8   8-9   9-10   12-13   12-17   13-14   14-15
15-16   16-17

```


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:Atom 24:CLASS 25:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 15:12:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -          410 TO ITERATE
```

100.0% PROCESSED 410 ITERATIONS 36 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6986 TO 9414


PROJECTED ANSWERS:

360 TO 1080

L2 36 SEA SSS SAM L1

=> d scan


L2 36 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Morpholinopropanoic acid, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, methyl ester
MF C24 H26 Cl2 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 36 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-, dihydrochloride (9CI)
MF C21 H22 Cl F N4 O3 . 2 Cl H




● 2 HC1

L2 36 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1,4-Oxazepine-4(5H)-carboximidamide, N-cyano-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]tetrahydro-
MF C23 H23 C12 N7 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 36 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Benzanide, N-[4-[(7-[[2-[(4-(4-fluorophenyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino)phenyl]-
MF C34 H33 F N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 11 full
FULL SEARCH INITIATED 15:12:57 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 8945 TO ITERATE


100.0% PROCESSED 8945 ITERATIONS
SEARCH TIME: 00.00.01

860 ANSWERS

L3 860 SEA SSS FUL L1

=> d scan

L3 860 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[(1-[2-(4-
morpholinyl)ethyl]-4-piperidinyl)methoxy]-
MF C28 H35 N5 O5
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
178.82 179.45

FILE 'CAPLUS' ENTERED AT 15:13:16 ON 24 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Mar 2008 VOL 148 ISS 13
FILE LAST UPDATED: 23 Mar 2008 (20080323/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13 and (pd<=20020715 or ad<=20020715 or prd<=20020715)
314 L3
22756406 PD<=20020715
(PD<=20020715)
4346067 AD<=20020715
(AD<=20020715)
3820052 PRD<=20020715
(PRD<=20020715)

L4 46 L3 AND (PD<=20020715 OR AD<=20020715 OR PRD<=20020715)

=> d 14 l-46 ibib hitstr

L4 ANSWER 1 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 20051004423 CAPLUS
DOCUMENT NUMBER: 143:312080
TITLE: Artificial blood vessel for delivering therapeutic agents
INVENTOR(S): Bhat, Vinayak D.; Yan, John
PATENT ASSIGNEE(S): Avantec Vascular Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S.
Ser. No. 206,807.
CODEN: USXKC0
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005203612	A1	20050915	US 2003-607836	20030627 <--
US 2002082677	A1	20020627	US 2001-782804	20010213 <--
US 7018405	B2	20060328		
US 2002114823	A1	20020822	US 2001-782927	20010213 <--
US 6471980	B2	20021029		
US 2002082679	A1	20020627	US 2001-2595	20011101 <--
US 2003083646	A1	20030501	US 2001-17500	20011214 <--
US 7077859	B2	20060718		
US 2003050692	A1	20030313	US 2002-206807	20020725 <--
US 2003017190	A1	20030123	US 2002-242334	20020911 <--
US 6858221	B2	20050222		
WO 2004010900	A1	20040205	WO 2003-US20492	20030627
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003261100	A1	20040216	AU 2003-261100	20030627
JP 2005533604	T	20051110	JP 2004-524538	20030627
US 2007142898	A1	20070621	US 2007-680439	20070228 <--
PRIORITY APPLN. INFO.:			US 2000-258024P	P 20001222 <--
			US 2001-782804	A2 20010213 <--
			US 2001-782927	A2 20010213 <--
			US 2001-783253	A2 20010213 <--
			US 2001-783254	A2 20010213 <--


US	2001-308381P	P	20010726	<--
US	2001-2595	A2	20011101	<--
US	2001-17500	A2	20011214	<--
US	2002-347473P	P	20020110	<--
US	2002-355317P	P	20020207	<--
US	2002-370703P	P	20020406	<--
US	2002-206807	A2	20020725	
US	2002-404624P	P	20020819	
US	2003-454146P	P	20030311	
US	2003-472536P	P	20030521	
WO	2003-US20492	W	20030627	

IT 443913-73-3, ZD6474

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(artificial blood vessel for delivering therapeutic agents)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



L4 ANSWER 2 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:995713 CAPLUS

DOCUMENT NUMBER: 141:420610

TITLE: Surface receptor complexes as biomarkers of disease
and for determination of treatment with dimer-acting
drugs

INVENTOR(S): Chan-Hui, Po-Ying; Dua, Rajiv; Mukherjee, Ali;
Pidaparthi, Sailaja; Salimi-Moosavi, Hossein; Shi,
Yining; Singh, Sharat

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U.S.
Ser. No. 623,057.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 32

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004229293	A1	20041118	US 2004-812619	20040330 <--
US 2003013126	A1	20030116	US 2002-154042	20020521 <--
US 7255999	B2	20070814		
US 2004126818	A1	20040701	US 2003-623057	20030717
US 7105308	B2	20060912		


US 2004197835	A1	20041007	US 2004-830543	20040422
US 7135300	B2	20061114		
AU 2004267420	A1	20050303	AU 2004-267420	20040810
CA 2535510	A1	20050303	CA 2004-2535510	20040810
WO 2005019470	A2	20050303	WO 2004-US25945	20040810
WO 2005019470	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1673399	A2	20060628	EP 2004-780731	20040810
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004013471	A	20061017	BR 2004-13471	20040810
JP 2007502417	T	20070208	JP 2006-523311	20040810
PRIORITY APPLN. INFO.:			US 2002-154042	A2 20020521 <--
			US 2002-398724P	P 20020725
			US 2003-459888P	P 20030401
			US 2003-623057	A2 20030717
			US 2003-494482P	P 20030811
			US 2003-508034P	P 20031001
			US 2003-512941P	P 20031020
			US 2003-523258P	P 20031118
			US 2001-292548P	P 20010521 <--
			US 2001-334901P	P 20011024 <--
			WO 2004-US25945	W 20040810

IT 443913-73-3, ZD6474

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(surface receptor complexes as biomarkers of disease or responsiveness
to treatment)

RN 443913-73-3 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



ACCESSION NUMBER: 2004:902199 CAPLUS
 DOCUMENT NUMBER: 1411374704
 TITLE: Composition and uses of galectin antagonists to augment treatment of cancer or other proliferative disorders
 INVENTOR(S): Chang, Yan; Sasak, Vodek
 PATENT ASSIGNEE(S): Glycogenesys, Inc., USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091634	A1	20041028	WO 2004-US10675	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2004023925	A1	20040205	US 2003-408723	20030407 <--
AU 2004229399	A1	20041028	AU 2004-229399	20040407
CA 2521649	A1	20041028	CA 2004-2521649	20040407
US 2004223971	A1	20041111	US 2004-819901	20040407
EP 1617849	A1	20060125	EP 2004-759200	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522163	T	20060928	JP 2006-509773	20040407
PRIORITY APPLN. INFO.:			US 2003-408723	A 20030407
			US 2003-461006P	P 20030407
			US 2003-474562P	P 20030530
			US 2001-299991P	P 20010621 <--
			US 2002-176235	A2 20020620 <--
			WO 2004-US10675	W 20040407

IT 443913-73-3, ZD6474
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition and uses of galectin antagonists to augment treatment of cancer or other proliferative disorders)
 RN 443913-73-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004182368 CAPLUS
 DOCUMENT NUMBER: 1401229401
 TITLE: Three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands
 INVENTOR(S): Come, Jon H.; Becker, Frank; Kley, Nikolai A.; Reichel, Christoph
 PATENT ASSIGNEE(S): Gpc Biotech Inc., USA; Gpc Biotech AG
 SOURCE: U.S. Pat. Appl. Publ., 238 pp., Cont.-in-part of U.S. Ser. No. 91,177.
 CODEN: USXEC0
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004043388	A1	20040304	US 2002-234985	20020903 <--
US 7135550	B2	20061114		
US 2003165873	A1	20030904	US 2002-91177	20020304 <--
EP 1832589	A1	20070912	EP 2007-8359	20021015 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK				
US 2004266854	A1	20041230	US 2004-820453	20040407 <--
PRIORITY APPLN. INFO.:			US 2001-272932P	P 20010302 <--
			US 2001-278233P	P 20010323 <--
			US 2001-329437P	P 20011015 <--
			US 2002-91177	A2 20020304 <--
			US 2001-336962P	P 20011203 <--
			WO 2002-US6677	A2 20020304 <--
			US 2002-234985	A2 20020903 <--
			EP 2002-797047	A3 20021015
			WO 2002-US33052	A2 20021015
			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223

IT 413599-62-9D, conjugates
 RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (three hybrid assay system for isolating ligand-binding polypeptides and for isolating small mol. ligands)

RN 413599-62-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]- (CA INDEX NAME)



L4 ANSWER 5 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:100803 CAPLUS
 DOCUMENT NUMBER: 140:139483
 TITLE: Method for enhancing the effectiveness of therapies of hyperproliferative diseases
 INVENTOR(S): Chang, Yan; Sasak, Vodek
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.
 CODEN: USXSC0
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004023925	A1	20040205	US 2003-408723	20030407 <--
US 2003013681	A1	20030116	US 2002-176235	20020620 <--
US 6680306	B2	20040120		
CN 1543351	A	20041103	CN 2002-816003	20020621 <--
US 2004043962	A1	20040304	US 2003-657383	20030908 <--
AU 2004229399	A1	20041028	AU 2004-229399	20040407
CA 2521649	A1	20041028	CA 2004-2521649	20040407
WO 2004091634	A1	20041028	WO 2004-US10675	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1617849	A1	20060125	EP 2004-759200	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006522163	T	20060928	JP 2006-509773	20040407
PRIORITY APPLN. INFO.:			US 2001-299991P	P 20010621 <--


US 2002-176235	A2 20020620 <--
US 2003-408723	A 20030407
US 2003-461006P	P 20030407
US 2003-474562P	P 20030530
WO 2004-US10675	W 20040407

IT 443913-73-3, ZD6474

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (method for enhancing effectiveness of therapies of hyperproliferative
 diseases)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



L4 ANSWER 6 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:60252 CAPLUS

DOCUMENT NUMBER: 140:128427

TITLE: Preparation of quinazolines as ephrin and EGFR
 receptor kinase modulators for treating cancer and
 other disorders

INVENTOR(S): Rice, Kenneth D.; Anand, Neel Kumar; Bussenius, Joerg;
 Costanzo, Simona; Kennedy, Abigail R.; Kim, Angie I.;
 Peto, Csaba J.; Tsang, Tsze H.; Blazey, Charles M.
 Exelixis, Inc., USA

PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 266 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006846	A2	20040122	WO 2003-US21923	20030714 <--
WO 2004006846	A3	20040715		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,			

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2491191 A1 20040122 CA 2003-2491191 20030714 <--
 AU 2003249212 A1 20040202 AU 2003-249212 20030714 <--
 EP 1521747 A2 20050413 EP 2003-764599 20030714 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006505509 T 20060216 JP 2004-521770 20030714 <--
 US 2006069077 A1 20060330 US 2005-522004 20050411 <--
 PRIORITY APPLN. INFO.: US 2002-396269P P 20020715 <--
 US 2003-447212P P 20030213
 WO 2003-US21923 W 20030714


OTHER SOURCE(S): MARPAT 140:128427
 IT 650579-40-1P 650579-55-8P 650579-56-9P
 650579-73-0P 650579-75-2P 650579-79-6P
 650579-84-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of quinazolines as ephrin and EGFR receptor kinase modulators for treating cancer and other disorders)
 RN 650579-40-1 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-(2-morpholinylmethoxy)- (CA INDEX NAME)




RN 650579-55-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[3-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 650579-56-9 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{5-(4-piperidinyl)-1,2,4-oxadiazol-3-yl]methoxy}- (CA INDEX NAME)




RN 650579-73-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[5-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 650579-75-2 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{3-(1-piperazinyl)-1,2,4-oxadiazol-5-yl]methoxy}- (CA INDEX NAME)



RN 650579-79-6 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4,5,6,7-tetrahydrotiazolo[5,4-c]pyridin-2-yl)methoxy]- (CA INDEX NAME)



RN 650579-84-3 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[2-(4-piperidinyl)-4-thiazolyl]methoxy]- (CA INDEX NAME)



IT 650577-76-7P 650577-79-0P 650577-80-3P
650577-81-4P 650577-82-5P 650577-83-6P
650577-89-2P 650577-90-5P 650577-91-6P
650577-92-7P 650577-93-8P 650577-96-1P
650578-03-3P 650578-07-7P 650578-08-8P
650578-09-9P 650578-10-2P 650578-11-3P
650578-18-0P 650578-19-1P 650578-20-4P
650578-23-7P 650578-24-8P 650578-25-9P
650578-26-0P 650578-28-2P 650578-29-3P
650578-30-6P 650578-31-7P 650578-32-8P
650578-33-9P 650578-34-0P 650578-35-1P
650578-41-9P 650578-50-0P 650578-51-1P
650578-52-2P 650578-53-3P 650578-54-4P
650578-55-5P 650578-56-6P 650578-57-7P
650578-58-8P 650578-59-9P 650578-60-2P
650578-61-3P 650578-65-7P 650578-68-0P
650578-70-4P 650579-37-6P 650579-41-2P
650579-42-3P 650579-43-4P 650579-44-5P
650579-45-6P 650579-46-7P 650579-48-9P
650579-50-3P 650579-52-5P 650579-57-0P
650579-58-1P 650579-59-2P 650579-60-5P
650579-61-6P 650579-62-7P 650579-64-9P

650579-67-2P 650579-68-3P 650579-69-4P
650579-76-3P 650579-77-4P 650579-80-9P
650579-81-0P 650579-85-4P 650579-86-5P
650579-87-6P 650579-88-7P 650579-89-8P
650579-90-1P 650579-91-2P 650579-92-3P
650579-93-4P 650579-94-5P 650579-95-6P
650579-96-7P 650579-97-8P 650579-98-9P
650579-99-0P 650580-00-0P 650580-01-1P
650580-02-2P 650580-03-3P 650580-04-4P
650580-05-5P 650580-06-6P 650580-07-7P
650580-08-8P 650580-09-9P 650580-10-2P
650580-11-3P 650580-12-4P 650580-13-5P
650580-15-7P 650580-16-8P 650580-17-9P
650580-23-7P 650580-24-8P 650580-25-9P
650580-27-1P 650580-29-3P 650580-31-7P
650580-32-8P 650580-33-9P 650580-34-0P
650580-38-4P 650580-39-5P 650580-40-8P
650580-41-9P 650580-42-0P 650580-43-1P
650580-44-2P 650580-45-3P 650580-46-4P
650580-47-5P 650580-48-6P 650580-49-7P
650580-50-0P 650580-51-1P 650580-52-2P
650580-53-3P 650580-54-4P 650580-55-5P
650580-56-6P 650580-57-7P 650580-58-8P
650580-59-9P 650580-60-2P 650580-61-3P
650580-62-4P 650580-63-5P 650580-64-6P
650580-65-7P 650580-66-8P 650580-67-9P
650580-68-0P 650580-69-1P 650580-72-6P
650580-73-7P 650580-74-8P 650580-75-9P
650580-76-0P 650580-77-1P 650580-78-2P
650580-79-3P 650580-80-6P 650580-81-7P
650580-82-8P 650580-83-9P 650580-84-0P
650580-85-1P 650580-86-2P 650580-87-3P
650580-88-4P 650580-89-5P 650580-90-8P
650580-91-9P 650580-92-0P 650580-93-1P
650580-94-2P 650580-95-3P 650580-96-4P
650580-97-5P 650580-98-6P 650580-99-7P
650581-00-3P 650581-01-4P 650581-02-5P
650581-03-6P 650581-04-7P 650581-05-8P
650581-06-9P 650581-07-0P 650581-08-1P
650581-09-2P 650581-10-5P 650581-11-6P
650581-12-7P 650581-13-8P 650581-14-9P
650581-15-0P 650581-16-1P 650581-17-2P
650581-18-3P 650581-19-4P 650581-20-7P
650581-21-8P 650581-22-9P 650581-23-0P
650581-24-1P 650581-25-2P 650581-26-3P
650581-27-4P 650581-28-5P 650581-29-6P
650581-30-9P 650581-31-0P 650581-32-1P
650581-33-2P 650581-34-3P 650581-35-4P
650581-36-5P 650581-37-6P 650581-38-7P
650581-39-8P 650581-40-1P 650581-41-2P
650581-42-3P 650581-43-4P 650581-44-5P
650581-45-6P 650581-46-7P 650581-47-8P
650581-48-9P 650581-49-0P 650581-50-3P
650581-51-4P 650581-52-5P 650581-53-6P
650581-54-7P 650581-55-8P 650581-56-9P
650581-57-0P 650581-58-1P 650581-59-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinazolines as ephrin and EGFR receptor kinase modulators for treating cancer and other disorders)

RN 650577-76-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-7-[(*(3S,8aS)*-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-yl)methoxy]-6-methoxy-, hydrochloride (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 650577-79-0 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(*(3S,8aS)*-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-yl)methoxy]-6-methoxy-, hydrochloride (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 650577-80-3 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(*(3R,8aR)*-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-yl)methoxy]-6-methoxy-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650577-81-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3R,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethoxy]-6-methoxy-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650577-82-5 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3S,8aR)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethoxy]-6-methoxy-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650577-83-6 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650577-89-2 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650577-90-5 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy-6-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650577-91-6 CAPLUS

CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy-6-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650577-92-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy]-6-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 650577-93-8 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[(octahydro-2H-quinolizin-3-yl)methoxy]- (CA INDEX NAME)



RN 650577-96-1 CAPLUS

CN Pyrrolo[1,2-a]pyrazin-1(2H)-one, 3-[[[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-2-methyl-, (3S,8aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 650578-03-3 CAPLUS

CN Pyrrolo[1,2-a]pyrazin-1(2H)-one, 3-[[[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-, (3S,8aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 650578-07-7 CAPLUS

CN Pyrrolo[1,2-a]pyrazin-1(2H)-one, 3-[[[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-, (3S,8aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 650578-08-8 CAPLUS

CN Pyrrolo[1,2-a]pyrazin-1(2H)-one, 3-[[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-, (3S,8aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 650578-09-9 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazin-1(6H)-one, 3-[[[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-, (3S,9aS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 650578-10-2 CAPLUS

CN 2H-Pyrido[1,2-a]pyrazin-1(6H)-one, 3-[[[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-, (3S,9aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 650578-11-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-[(3aR,6aS)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 650578-18-0 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5b,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-19-1 CAPLUS
 CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-6-methoxy-7-[(3 α d,5 β ,6 α a)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-20-4 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[(3 α d,5 β ,6 α a)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-23-7 CAPLUS
 CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-6-methoxy-7-
 [(3aa,5beta,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-
 yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-24-8 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-6-methoxy-7-
 [(3aa,5beta,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-
 yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-25-9 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-
 [[(3aa,5β,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-
 yl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-26-0 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-
 [[(3aa,5β,6aa)-octahydro-2-(1-methylethyl)cyclopenta[c]pyrrol-5-yl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-28-2 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5B,6aa)-octahydro-2-(1-methylethyl)cyclopenta[c]pyrrol-5-yl]methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-29-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-7-[(3aa,5B,6aa)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 650578-30-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(3aa,5aa)-octahydro-2-(2-methylpropyl)cyclopenta[c]pyrrol-5-yl]methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 650578-31-7 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5aa)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-32-8 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-
[[3aa,5β,6aa)-octahydro-2-(2-
methylpropyl)cyclopenta[c]pyrrol-5-yl]methoxy]-, hydrochloride (9CI) (CA
INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-33-9 CAPLUS
CN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 5-[[[4-[(4-bromo-3-chloro-2-
fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-, ethyl
ester, hydrochloride, (3aa,5β,6aa)- (9CI) (CA INDEX
NAME)


Relative stereochemistry.



● x HCl

RN 650578-34-0 CAPLUS
 CN Cyclopenta[c]pyrrole, 5-[[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxylmethyl]octahydro-2-(methylsulfonyl)-, hydrochloride, (3aa,5β,6aa)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl

RN 650578-35-1 CAPLUS
 CN Cyclopenta[c]pyrrole, 2-acetyl-5-[[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxylmethyl]octahydro-, hydrochloride, (3aa,5β,6aa)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● x HCl


RN 650578-41-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 650578-50-0 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl)methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 650578-51-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650578-52-2 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 650578-53-3 CAPLUS
 CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 650578-54-4 CAPLUS
 CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 650578-55-5 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 650578-56-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 650578-57-7 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl

RN 650578-58-8 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650578-59-9 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650578-60-2 CAPLUS

CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650578-61-3 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl)methoxy]-6-methoxy-, hydrochloride
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 650578-65-7 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)methoxy]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● x HCl

RN 650578-68-0 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(8aR)-tetrahydro-1H,3H-thiazolo[4,3-c][1,4]oxazin-3-yl)methoxy]-, trifluoroacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 650580-15-7

CMF C22 H22 Cl2 N4 O3 S

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 650578-70-4 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]ethoxy]-, hydrochloride, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 650579-37-6 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650579-41-2 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-(phenylmethyl)-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650579-42-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650579-43-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-4-methyl-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650579-44-5 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(4-ethylhexahydro-1,4-oxazepin-2-yl)methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 650579-45-6 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(tetrahydro-2H-pyran-2-yl)methoxy]- (CA INDEX NAME)




RN 650579-46-7 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(2-[(dimethylamino)methyl]-4-thiazolyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650579-48-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{2-[4-morpholinylmethyl]-4-thiazolyl]methoxy]- (CA INDEX NAME)




RN 650579-50-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{2-[4-methyl-1-piperazinyl)methyl]-4-thiazolyl}methoxy]- (CA INDEX NAME)




RN 650579-52-5 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{5-(1-methyl-4-piperidinyl)-1,2,4-oxadiazol-3-yl}methoxy]- (CA INDEX NAME)




RN 650579-57-0 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{5-[(dimethylamino)methyl]-1,2,4-oxadiazol-3-yl}methoxy]-6-methoxy- (CA INDEX NAME)




RN 650579-58-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-(3-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)




RN 650579-59-2 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-(1-methyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)




RN 650579-60-5 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-(2-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)



RN 650579-61-6 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-(1-methyl-2-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 650579-62-7 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-(1-ethyl-2-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 650579-64-9 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{[3-[(4-methyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-5-yl]methoxy}-] (CA INDEX NAME)




RN 650579-67-2 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{[3-[(dimethylamino)methyl]-1,2,4-oxadiazol-5-yl]methoxy}-]6-methoxy- (CA INDEX NAME)



RN 650579-68-3 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{3-(4-morpholinylmethyl)-1,2,4-oxadiazol-5-yl]methoxy]- (CA INDEX NAME)




RN 650579-69-4 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{3-(4-methyl-1-piperazinyl)-1,2,4-oxadiazol-5-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 650579-76-3 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{3-(4-ethyl-1-piperazinyl)-1,2,4-oxadiazol-5-yl}methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 650579-77-4 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 650579-80-9 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-ethyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 650579-81-0 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(1-methyl-4-piperidinyl)-4-thiazolyl)methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 650579-85-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(2-(1-ethyl-4-piperidinyl)-4-thiazolyl)methoxy]-6-methoxy-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 650579-86-5 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-87-6 CAPLUS

CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-88-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-89-8 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 650579-90-1 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 650579-91-2 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-92-3 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 650579-93-4 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650579-94-5 CAPLUS

CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-95-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-96-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-7-[(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-97-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-98-9 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-7-[(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-yl]methoxy]-6-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650579-99-0 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3R,8aR)-hexahydro-1H-pyrrololo[2,1-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-00-0 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3S,8aR)-hexahydro-1H-pyrrololo[2,1-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-01-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-02-2 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3R,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-03-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-04-4 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 650580-05-5 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-7-[(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-yl]methoxy-6-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 650580-06-6 CAPLUS
 CN D-xylo-Hexitol, 1,4:3,6-dianhydro-5-[[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-5-deoxy-2-O-methyl-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-07-7 CAPLUS

CN D-Glucitol, 1,4:3,6-dianhydro-5-deoxy-5-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-08-8 CAPLUS

CN D-xylo-Hexitol, 1,4:3,6-dianhydro-5-deoxy-5-[[[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-O-methyl-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-09-9 CAPLUS

CN D-xylo-Hexitol, 1,4:3,6-dianhydro-5-[[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-5-deoxy-2-O-methyl-, (5\x)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-10-2 CAPLUS

CN D-xylo-Hexitol, 1,4:3,6-dianhydro-5-[[[4-[(3-chloro-2,4-difluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-5-deoxy-2-O-methyl-, (5\x)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-11-3 CAPLUS

CN D-Glucitol, 1,4:3,6-dianhydro-5-[[[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-5-deoxy-2-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-12-4 CAPLUS

CN D-xylo-Hexitol, 1,4:3,6-dianhydro-5-deoxy-5-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-O-methyl-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-13-5 CAPLUS

CN D-Glucitol, 1,4:3,6-dianhydro-5-deoxy-5-[[[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-O-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-15-7 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[((8aR)-tetrahydro-1H,3H-thiazolo[4,3-c][1,4]oxazin-3-yl)methoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 650580-16-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ethoxy]- (CA INDEX NAME)




RN 650580-17-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)methoxy]- (CA INDEX NAME)




RN 650580-23-7 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-(1-methyl-2-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)




RN 650580-24-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-(4-thiazolylmethoxy)- (CA INDEX NAME)




RN 650580-25-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-(3-pyridinylmethoxy)-
(CA INDEX NAME)



RN 650580-27-1 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(tetrahydro-2-furanyl)methoxy]- (CA INDEX NAME)



RN 650580-29-3 CAPLUS


CN α-D-Glucopyranoside, methyl 6-O-[4-((3,4-dichlorophenyl)amino)-6-methoxy-7-quinazolinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 650580-31-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[3-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1,2,4-oxadiazol-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 650580-32-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[4-[4-(1-pyrrolidinyl)phenyl]-2-thiazolyl]methoxy]- (CA INDEX NAME)




RN 650580-33-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[[4-[4-(diethylamino)phenyl]-2-thiazolyl]methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-34-0 CAPLUS


CN Benzamide, 5-[2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-thiazolyl]-2-hydroxy- (CA INDEX NAME)




RN 650580-38-4 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[2-(1,3-dioxolan-2-yl)ethoxy]-
6-methoxy- (CA INDEX NAME)



RN 650580-39-5 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[2-(1,3-dioxan-2-yl)ethoxy]-6-
methoxy- (CA INDEX NAME)




RN 650580-40-8 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-(4-
morpholinyl)ethoxy]- (CA INDEX NAME)




RN 650580-41-9 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 650580-42-0 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 650580-43-1 CAPLUS
CN 1H-Isindole-1,3(2H)-dione, 2-[2-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 650580-44-2 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[4-(3-pyridinyl)-2-

thiazolyl]methoxy]- (CA INDEX NAME)




RN 650580-45-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[4-(2-pyridinyl)-2-thiazolyl]methoxy]- (CA INDEX NAME)



RN 650580-46-4 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[4-(4-pyridinyl)-2-thiazolyl]methoxy]- (CA INDEX NAME)



RN 650580-47-5 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-(4-morpholinyl)-

4-thiazolyl]methoxy]- (CA INDEX NAME)




RN 650580-48-6 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(3-(4-morpholinyl)-1,2,4-oxadiazol-5-yl)methoxy]- (CA INDEX NAME)




RN 650580-49-7 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3-(dimethylamino)-1,2,4-oxadiazol-5-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-50-0 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[4-[(4-methyl-1-piperazinyl)methyl]-2-thiazolyl]methoxy]- (CA INDEX NAME)




RN 650580-51-1 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[4-(4-morpholinylmethyl)-2-thiazolyl]methoxy]- (CA INDEX NAME)



RN 650580-52-2 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-2-thiazolyl]methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-53-3 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[5-(phenylmethoxy)methyl]-1,2,4-oxadiazol-3-yl]methoxy]- (CA INDEX NAME)




BN 650580-54-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(4-ethyl-2-morpholinyl)methoxy]-6-methoxy- (CA INDEX NAME)




BN 650580-55-5 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[2-(1-methyl-4-piperidinyl)-4-thiazolyl]methoxy]- (CA INDEX NAME)




RN 650580-56-6 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(3-(4-methyl-1-piperazinyl)-1,2,4-oxadiazol-5-yl)methoxy]- (CA INDEX NAME)




RN 650580-57-7 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-(1-ethyl-2-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-58-8 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3-(4-ethyl-1-piperazinyl)-1,2,4-oxadiazol-5-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-59-9 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-(4-methoxyphenyl)-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)




RN 650580-60-2 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-[4-(trifluoromethyl)phenyl]-4-thiazolyl)methoxy]- (CA INDEX NAME)



RN 650580-61-3 CAPLUS
CN 4-Quinazolinamine, 7-[(2-(4-chlorophenyl)-4-thiazolyl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650580-62-4 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-63-5 CAPLUS

CN 4-Quinazolinamine, 7-[(5-chlorobenzo[b]thien-3-yl)methoxy]-N-(3,4-dichlorophenyl)- (CA INDEX NAME)




RN 650580-64-6 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3-[4-(1,1-dimethylethyl)phenyl]-1,2,4-oxadiazol-5-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-65-7 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy}- (CA INDEX NAME)




RN 650580-66-8 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]methoxy}- (CA INDEX NAME)




RN 650580-67-9 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{1-(phenylmethyl)-1H-imidazol-2-yl]methoxy}- (CA INDEX NAME)




RN 650580-68-0 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl}methoxy]-6-methoxy- (CA INDEX NAME)



RN 650580-69-1 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{(6-fluoro-4H-1,3-benzodioxin-8-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-72-6 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{3-[(2-pyridinylsulfonyl)methyl]-1,2,4-oxadiazol-5-yl}methoxy]- (CA INDEX NAME)




RN 650580-73-7 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-phenyl-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)




RN 650580-74-8 CAPLUS

CN 4-Quinazolinamine, 7-[(4-chloro-2-(trifluoromethyl)-6-quinolinyl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650580-75-9 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(1-methyl-2-pyrrolidinyl)ethoxy)-2-(1-methyl-2-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 650580-76-0 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-(1-ethyl-4-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650580-77-1 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-(1-ethyl-3-piperidinyl)-1,2,4-oxadiazol-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-78-2 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(2-(dimethylamino)-4-thiazolyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-79-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(4-ethylhexahydro-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650580-80-6 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(2-(1-ethyl-4-piperidinyl)-4-thiazolyl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650580-81-7 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(3-(2S)-2-pyrrolidinyl-1,2,4-oxadiazol-5-yl)methoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-82-8 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(2S)-2-pyrrolidinyl-4-thiazolyl)methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 650580-83-9 CAPLUS


CN 2-Thiazoledemethanol, 4-[[[4-((3,4-dichlorophenyl)amino)-6-methoxy-7-quinazolinyl]oxy]methyl]-, benzoate (ester) (9CI) (CA INDEX NAME)



RN 650580-84-0 CAPLUS
CN 2-Thiazolemethanol, 4-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)




RN 650580-85-1 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4,5,6,7-tetrahydro-5-methylthiazolo[5,4-c]pyridin-2-yl)methoxy]- (CA INDEX NAME)




RN 650580-86-2 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(4S)-4-thiazolidinyl-4-thiazolyl)methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 650580-87-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(2-piperidinyl)-4-thiazolyl)methoxy]- (CA INDEX NAME)




RN 650580-88-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(1-methyl-2-piperidinyl)-4-thiazolyl)methoxy]- (CA INDEX NAME)




RN 650580-89-5 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{2-(3-piperidinyl)-4-thiazolyl]methoxy]- (CA INDEX NAME)




RN 650580-90-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{2-(1-methyl-3-piperidinyl)-4-thiazolyl]methoxy]- (CA INDEX NAME)




RN 650580-91-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{2-(1-ethyl-2-piperidinyl)-4-thiazolyl]methoxy]-6-methoxy- (CA INDEX NAME)



RN 650580-92-0 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(2-(1-ethyl-3-piperidinyl)-4-thiazolyl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650580-93-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(3-[(2S)-1-ethyl-2-pyrrolidinyl]-1,2,4-oxadiazol-5-yl)methoxy]-6-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650580-94-2 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(2-[(2S)-1-ethyl-2-pyrrolidinyl]-4-thiazolyl)methoxy]-6-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 650580-95-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-ethyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-96-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-4-propyl-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650580-97-5 CAPLUS

CN 4-Quinazolinamine, 7-[(4-(cyclopropylmethyl)hexahydro-1,4-oxazepin-2-yl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650580-98-6 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-4-(2-methoxyethyl)-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650580-99-7 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-4-(1-methylethyl)-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650581-00-3 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(1-piperazinyl)-

4-thiazolyl]methoxy]- (CA INDEX NAME)




RN 650581-01-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-(2-pyrrolidinyl)-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)



RN 650581-02-5 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-(1-ethyl-2-pyrrolidinyl)-1,2,4-oxadiazol-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-03-6 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(3-[(2S)-1-methyl-2-((R,S)-diphenylphosphino)propanyl]phenyl)-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)

pyrrolidinyl]-1,2,4-oxadiazol-5-yl]methoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 650581-04-7 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-[(2S)-1-methyl-2-pyrrolidinyl]-4-thiazolyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 650581-05-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(2-(4-ethyl-1-piperazinyl)-4-thiazolyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-06-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(1,4-dimethyl-2-piperazinyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-07-0 CAPLUS

CN 4-Quinazolinamine, 7-[(4-cyclopentyl-2-morpholinyl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650581-08-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{4-(1-methylethyl)-2-morpholinyl]methoxy}- (CA INDEX NAME)




RN 650581-09-2 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{4-(3-phenylpropyl)-2-morpholinyl}methoxy]- (CA INDEX NAME)




RN 650581-10-5 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{4-(2-methoxyethyl)-2-morpholinyl}methoxy]- (CA INDEX NAME)




RN 650581-11-6 CAPLUS


CN 4-Morpholineacetic acid, 2-{[(4-(3,4-dichlorophenyl)amino)-6-methoxy-7-quinazolinyl]oxy}-2-methyl-, ethyl ester (CA INDEX NAME)



RN 650581-12-7 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{4-(5-hexenyl)-2-morpholinyl]methoxy}-6-methoxy- (9CI) (CA INDEX NAME)




RN 650581-13-8 CAPLUS
 CN Ethanol, 2-[2-[2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-morpholinyl]ethoxy]- (CA INDEX NAME)




RN 650581-14-9 CAPLUS
 CN 4-Morpholinepropanoic acid, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-

quinazolinyl]oxy)methyl]-, methyl ester (CA INDEX NAME)




RN 650581-15-0 CAPLUS

CN 4-Morpholinehexanenitrile, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]- (CA INDEX NAME)




RN 650581-16-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[4-[(tetrahydro-2H-pyran-2-yl)methyl]-2-morpholiny]methoxy]- (CA INDEX NAME)




RN 650581-17-2 CAPLUS

CN 4-Morpholinebutanenitrile, 2-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)




RN 650581-18-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-19-4 CAPLUS


CN 4-Morpholinepentanoic acid, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, methyl ester (CA INDEX NAME)




RN 650581-20-7 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[(4-(7-octenyl)-2-morpholinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 650581-21-8 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-propyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-22-9 CAPLUS
CN 4-Morpholinehexanol, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)




RN 650581-23-0 CAPLUS
CN Morpholine, 4-acetyl-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 650581-24-1 CAPLUS
CN 4-Quinazolinamine, 7-[(4-(cyclopropylmethyl)-2-morpholinyl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650581-25-2 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-(2-propynyl)-2-morpholinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 650581-26-3 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[4-(4-pyridinyl)-2-morpholinyl]methoxy]- (CA INDEX NAME)




RN 650581-27-4 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[4-(2-pyridinylmethyl)-2-morpholinyl]methoxy]- (CA INDEX NAME)




RN 650581-28-5 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[4-(2-pentynyl)-2-morpholinyl]methoxy]- (9CI) (CA INDEX NAME)




RN 650581-29-6 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{2-(4-methyl-1-piperazinyl)-4-thiazolyl]methoxy]- (CA INDEX NAME)



RN 650581-30-9 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{5-(1-methyl-2-pyrrolidinyl)-1,2,4-oxadiazol-3-yl]methoxy]- (CA INDEX NAME)




RN 650581-31-0 CAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-methoxy-7-[{(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-32-1 CAPLUS

CN Piperazine, 4-acetyl-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1-ethyl- (9CI) (CA INDEX NAME)




RN 650581-33-2 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2,5-dimethoxyphenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-34-3 CAPLUS

CN 4-Quinazolinamine, N-(3-bromo-2-methylphenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-35-4 CAPLUS

CN 4-Quinazolinamine, 6-methoxy-7-[(4-methyl-2-morpholiny) methoxy]-N-(3,4,5-trichlorophenyl)- (CA INDEX NAME)




RN 650581-36-5 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-methylphenyl)-6-methoxy-7-[(4-methyl-2-morpholiny) methoxy]- (CA INDEX NAME)




RN 650581-37-6 CAPLUS


CN 1,4-Oxazepine, 2-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-4-(1-iminoethyl)- (9CI) (CA INDEX NAME)




RN 650581-38-7 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)



RN 650581-39-8 CAPLUS
 CN 4-Quinazolinamine, N-(5-chloro-2-fluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-40-1 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-41-2 CAPLUS

CN 4-Quinazolinamine, N-(2,4-dichlorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-42-3 CAPLUS

CN 4-Quinazolinamine, N-(2,4-dibromophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-43-4 CAPLUS


CN 4-Quinazolinamine, 6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]-N-(2,4-trichlorophenyl)- (CA INDEX NAME)




RN 650581-44-5 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(1-ethyl-4-methyl-2-piperazinyl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650581-45-6 CAPLUS
 CN 4-Morpholinecarboximidamide, N-cyano-2-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)




RN 650581-46-7 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(1-pyrrolidinylmethyl)-4-thiazolyl)methoxy- (CA INDEX NAME)




RN 650581-47-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[4-(tetrahydro-2H-pyran-4-yl)-2-morpholinyl]methoxy- (CA INDEX NAME)




RN 650581-48-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[4-(2-ethylbutyl)-2-morpholinyl]methoxy-6-methoxy- (CA INDEX NAME)




RN 650581-49-0 CAPLUS

CN 4-Quinazolinamine, 7-[4-(cyclohexylmethyl)-2-morpholinyl]methoxy-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650581-50-3 CAPLUS

CN 4-Morpholineethanol, 2-[[[4-((3,4-dichlorophenyl)amino)-6-methoxy-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)



RN 650581-51-4 CAPLUS


CN 4-Quinazolinamine, 7-[[4-(2-butynyl)-2-morpholinyl]methoxy]-N-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 650581-52-5 CAPLUS


CN 4-Quinazolinamine, 7-[(4-cyclobutyl-2-morpholinyl)methoxy]-N-(3,4-

dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650581-53-6 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(4-[(2-(1,3-dioxolan-2-yl)ethyl]morpholinyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-54-7 CAPLUS

CN 4-Quinazolinamine, 7-[(4-(2-cyclohexylethyl)morpholinyl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650581-55-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{4-[2-(1,3-dioxan-2-yl)ethyl]-2-morpholinyl}methoxy]- (CA INDEX NAME)



RN 650581-56-9 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{4-[2-(4-pentenyl)-2-morpholinyl]methoxy}- (9CI) (CA INDEX NAME)



RN 650581-57-0 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{4-[(2R)-2-methylbutyl]-2-morpholinyl}methoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 650581-58-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(4-(4-fluorobutyl)-2-morpholinyl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650581-59-2 CAPLUS

CN 2-Butanone, 3-[2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-morpholinyl- (CA INDEX NAME)



IT 650581-60-5P 650581-61-6P 650581-62-7P


650581-63-8P 650581-64-9P 650581-65-0P
650581-66-1P 650581-67-2P 650581-68-3P
650581-69-4P 650581-70-7P 650581-71-8P
650581-72-9P 650581-73-0P 650581-74-1P
650581-77-4P 650581-78-5P 650581-79-6P
650581-80-9P 650581-81-0P 650581-82-1P
650581-83-2P 650581-84-3P 650581-85-4P
650581-86-5P 650581-87-6P 650581-88-7P
650581-89-8P 650581-90-1P 650581-91-2P
650581-92-3P 650581-93-4P 650581-94-5P
650581-95-6P 650581-96-7P 650581-97-8P
650581-98-9P 650581-99-0P 650582-00-6P
650582-01-7P 650582-02-8P 650582-03-9P
650582-04-0P 650582-05-1P 650582-06-2P
650582-07-3P 650582-08-4P 650582-09-5P
650582-10-8P 650582-11-9P 650582-12-0P
650582-13-1P 650582-16-4P 650582-17-5P
650582-18-6P 650582-19-7P 650582-20-0P
650582-21-1P 650582-24-4P 650582-25-5P
650582-27-7P 650582-28-8P 650582-29-9P
650582-30-2P 650582-31-3P 650582-32-4P
650582-33-5P 650582-34-6P 650582-35-7P
650582-36-8P 650582-37-9P 650582-38-0P
650582-39-1P 650582-40-4P 650582-41-5P
650582-42-6P 650582-43-7P 650582-44-8P
650582-45-9P 650582-46-0P 650582-47-1P
650582-48-2P 650582-49-3P 650582-50-6P
650582-51-7P 650582-52-8P 650582-53-9P
650582-54-0P 650582-55-1P 650582-56-2P
650582-57-3P 650582-58-4P 650582-59-5P
650582-60-8P 650582-61-9P 650582-62-0P
650582-63-1P 650582-64-2P 650582-65-3P
650582-66-4P 650582-67-5P 650582-68-6P
650582-95-9P 650582-96-0P 650582-97-1P
650582-98-2P 650582-99-3P 650583-00-9P
650583-01-0P 650583-02-1P 650583-03-2P
650583-04-3P 650583-08-7P 650583-09-8P
650583-10-1P 650583-11-2P 650583-12-3P
650583-13-4P 650583-14-5P 650583-15-6P
650583-16-7P 650583-17-8P 650583-18-9P
650583-19-0P 650583-21-4P 650583-22-5P
650583-23-6P 650583-24-7P 650583-25-8P
650583-26-9P 650583-27-0P 650583-29-2P
650583-30-5P 650583-32-7P 650583-34-9P
650583-35-0P 650583-36-1P 650583-37-2P
650583-38-3P 650583-39-4P 650583-40-7P
650583-62-3P 651031-01-5P 651031-02-6P
651031-03-7P 651031-04-8P 651031-05-9P
651031-06-0P 651031-07-1P 651031-08-2P
732983-39-0P 752201-22-2P 756475-26-0P
756816-98-5P 772338-00-8P 778574-40-6P
781613-23-8P 785775-35-1P 787547-48-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of quinazolines as ephrin and EGFR receptor kinase modulators for treating cancer and other disorders)

RN 650581-60-5 CAPLUS


CN 2-Butanone, 1-[2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl)oxy]methyl]-4-morpholinyl]- (CA INDEX NAME)




RN 650581-61-6 CAPLUS
 CN 4-Quiazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-pentyl-2-morpholinyl)methoxy]- (CA INDEX NAME)



RN 650581-62-7 CAPLUS
 CN 4-Quiazolinamine, N-(3,4-dichlorophenyl)-7-[(4-hexyl-2-morpholinyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-63-8 CAPLUS
 CN 4-Quiazolinamine, N-(3,4-dichlorophenyl)-7-[(4-heptyl-2-morpholinyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-64-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{(4-octyl-2-morpholiny) methoxy}-] (CA INDEX NAME)




RN 650581-65-0 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{(4-(2-phenylethyl)-2-morpholiny) methoxy}-] (CA INDEX NAME)




RN 650581-66-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{(4-butyl-2-morpholiny) methoxy}-] (CA INDEX NAME)




RN 650581-67-2 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-(2-propenyl)-2-morpholinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 650581-68-3 CAPLUS

CN Ethanone, 2-[2-[[[4-((3,4-dichlorophenyl)amino)-6-methoxy-7-quinazolinyl]oxy]methyl]-4-morpholinyl]-1-phenyl- (CA INDEX NAME)




RN 650581-69-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(4-(2-fluoroethyl)-2-morpholinyl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650581-70-7 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-(3-methyl-2-butienyl)-2-morpholinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 650581-71-8 CAPLUS

CN 4-Quinazolinamine, 7-[(4-[(2E)-3-bromo-2-propenyl]-2-morpholinyl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 650581-72-9 CAPLUS
CN 4-Morpholineacetamide, 2-[[[4-(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)




RN 650581-73-0 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[[hexahydro-4-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]-1,4-oxazepin-2-yl]methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-74-1 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[[hexahydro-4-(3-methylbutyl)-1,4-oxazepin-2-yl]methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-77-4 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[[(4-(2-ethylbutyl)hexahydro-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650581-78-5 CAPLUS
 CN 1,4-Oxazepine, 2-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methylhexahydro-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 650581-79-6 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-(1-methyl-4-piperidinyl)-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650581-80-9 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2-fluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)



RN 650581-81-0 CAPLUS


CN 1,4-Oxazepine-4(5H)-carboximidamide, N-cyano-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]tetrahydro- (CA INDEX NAME)



RN 650581-82-1 CAPLUS


CN 4-Quinazolinamine, N-(3-bromo-4-methylphenyl)-6-methoxy-7-[(4-methyl-2-

morpholinyl)methoxy] - (CA INDEX NAME)




RN 650581-83-2 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(1,4-diethyl-2-piperazinyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650581-84-3 CAPLUS

CN 1-Piperidinecarboximidamide, 4-[[[4-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-N-cyano- (CA INDEX NAME)




RN 650581-85-4 CAPLUS

CN Morpholine, 2-[[[4-((3,4-dichlorophenyl)amino)-6-methoxy-7-
quinazolinyl]oxy]methyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 650581-86-5 CAPLUS

CN Morpholine, 2-[[[4-((3,4-dichlorophenyl)amino)-6-methoxy-7-
quinazolinyl]oxy]methyl]-4-((phenylmethyl)sulfonyl)- (9CI) (CA INDEX
NAME)




RN 650581-87-6 CAPLUS

CN Morpholine, 2-[[[4-((3,4-dichlorophenyl)amino)-6-methoxy-7-
quinazolinyl]oxy]methyl]-4-((4-fluorophenyl)sulfonyl)- (9CI) (CA INDEX
NAME)




RN 650581-88-7 CAPLUS

CN Morpholine, 2-[[[4-(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(ethylsulfonyl)- (9CI) (CA INDEX NAME)



RN 650581-89-8 CAPLUS


CN Morpholine, 2-[[[4-(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 650581-90-1 CAPLUS


CN Morpholine, 4-[(3-chloropropyl)sulfonyl]-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 650581-91-2 CAPLUS

CN Morpholine, 4-(butylsulfonyl)-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 650581-92-3 CAPLUS


CN Morpholine, 2-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl-4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 650581-93-4 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-[(3,5-dimethyl-4-isoxazolyl)carbonyl]- (9CI)
(CA INDEX NAME)



RN 650581-94-5 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-[(3-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 650581-95-6 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(2-methyl-1-oxopentyl)- (9CI) (CA INDEX NAME)




RN 650581-96-7 CAPLUS

CN Morpholine, 4-(4-butylbenzoyl)-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 650581-97-8 CAPLUS

CN Morpholine, 4-[(4-chlorophenyl)acetyl]-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 650581-98-9 CAPLUS

CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(1-oxo-2-propylpentyl)- (9CI) (CA INDEX NAME)




RN 650581-99-0 CAPLUS

CN Morpholine, 2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-4-(4-methyl-1-oxopentyl)- (9CI) (CA INDEX NAME)



RN 650582-00-6 CAPLUS


CN Morpholine, 2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-4-(2,5-difluorobenzoyl)- (9CI) (CA INDEX NAME)



RN 650582-01-7 CAPLUS


CN Morpholine, 4-(cyclopentylcarbonyl)-2-[(4-[(3,4-dichlorophenyl)amino]-6-

methoxy-7-quinazolinyl]oxy]methyl)- (9CI) (CA INDEX NAME)




RN 650582-02-8 CAPLUS

CN Morpholine, 2-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(1-oxo-2-phenylbutyl)- (9CI) (CA INDEX NAME)




RN 650582-03-9 CAPLUS


CN Morpholine, 2-[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(2,3,6-trifluorobenzoyl)- (9CI) (CA INDEX NAME)




RN 650582-04-0 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(3-furanylcarbonyl)- (9CI) (CA INDEX NAME)




RN 650582-05-1 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 650582-06-2 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(1-oxohexyl)- (9CI) (CA INDEX NAME)




RN 650582-07-3 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(2-ethyl-1-oxohexyl)- (9CI) (CA INDEX NAME)



RN 650582-08-4 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(1-oxo-3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 650582-09-5 CAPLUS
CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 650582-10-8 CAPLUS

CN Morpholine, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-(1-naphthalenylcarbonyl)- (9CI) (CA INDEX NAME)




RN 650582-11-9 CAPLUS


CN Morpholine, 4-[(2-chloro-3-pyridinyl)carbonyl]-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 650582-12-0 CAPLUS
CN Morpholine, 4-[(6-chloro-3-pyridinyl)carbonyl]-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxylmethyl]- (9CI) (CA INDEX NAME)



RN 650582-13-1 CAPLUS
CN Morpholine, 4-(1,3-benzodioxol-5-ylcarbonyl)-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxylmethyl]- (9CI) (CA INDEX NAME)




RN 650582-16-4 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-ethoxy-7-(2-morpholinylmethoxy)- (CA INDEX NAME)




RN 650582-17-5 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-ethoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-18-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-methylphenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-19-7 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-3-methylphenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-20-0 CAPLUS
 CN 4-Morpholinecarboximidamide, N-cyano-2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-N'-methyl- (CA INDEX NAME)



RN 650582-21-1 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-3-chlorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-24-4 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-chlorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-25-5 CAPLUS

CN 1,4-Oxazepine, 4-acetyl-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro- (9CI) (CA INDEX NAME)




RN 650582-27-7 CAPLUS

CN 4-Quinazolinamine, N-(3-bromo-4-chlorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-28-8 CAPLUS

CN 4-Morpholinepropanoic acid, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-β-oxo- (CA INDEX NAME)




RN 650582-29-9 CAPLUS

CN 4-Morpholinebutanoic acid, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- γ -oxo-, methyl ester (CA INDEX NAME)




RN 650582-30-2 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4-methyl-3-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-31-3 CAPLUS

CN 4-Quinazolinamine, N-(3-bromo-2-chlorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-32-4 CAPLUS

CN 4-Morpholinecarboximidamide, N-cyano-2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)



RN 650582-33-5 CAPLUS


CN 4-Morpholinecarboximidamide, N-cyano-2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-N'-ethyl- (CA INDEX NAME)



RN 650582-34-6 CAPLUS

CN Morpholine, 4-[(E)-(cyanoimino)-1-piperidinylmethyl]-2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 650582-35-7 CAPLUS

CN Morpholine, 4-[(E)-(cyanoimino)-1-pyrrolidinylmethyl]-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 650582-36-8 CAPLUS


CN Morpholine, 4-[(E)-(cyanoimino)(4-methyl-1-piperazinyl)methyl]-2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 650582-37-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(6-ethyl-4,6-dimethyl-2-morpholinyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650582-38-0 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-methylphenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-39-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(6,6-dimethyl-2-morpholinyl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650582-40-4 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4,6,6-trimethyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-41-5 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[2-(5,5-dimethyl-2-morpholinyl)ethoxy]-6-methoxy- (CA INDEX NAME)




RN 650582-42-6 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-(4,5,5-trimethyl-2-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 650582-43-7 CAPLUS
 CN 4-Morpholinecarboxylic acid, 2-[2-[(4-(3,4-dichlorophenyl)amino)-6-methoxy-7-quinazolinyl]oxy]ethyl-5,5-dimethyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 650582-44-8 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(4,5,5-trimethyl-2-morpholinyl)methoxy]- (CA INDEX NAME)



RN 650582-45-9 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-46-0 CAPLUS
CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-47-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-(4,6,6-trimethyl-2-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 650582-48-2 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2,3-difluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-49-3 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-2,5-difluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-50-6 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-3,5-difluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)



RN 650582-51-7 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichloro-2-methylphenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-52-8 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-methylphenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-53-9 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-54-0 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-55-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-56-2 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-57-3 CAPLUS

CN 4-Quinazolinamine, N-(2,3-dichloro-4-methylphenyl)-6-methoxy-7-[(4-methyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-58-4 CAPLUS

CN 2-Morpholinone, 6-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-3,3,4-trimethyl- (CA INDEX NAME)




RN 650582-59-5 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-6-methoxy-7-[(4,5,5-trimethyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-60-8 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-6-methoxy-7-[(4,5,5-trimethyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650582-61-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[(4,5,5-trimethyl-2-morpholinyl)methoxy]- (CA INDEX NAME)



RN 650582-62-0 CAPLUS


CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-6-methoxy-7-[(4,5,5-trimethyl-2-morpholinyl)methoxy]- (CA INDEX NAME)



RN 650582-63-1 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-[(2S)-4,5,5-trimethyl-2-morpholinyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 650582-64-2 CAPLUS


CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-6-methoxy-7-[(4,5,5-trimethyl-2-morpholinyl)methoxy]- (CA INDEX NAME)



RN 650582-65-3 CAPLUS

CN Piperazinone, 6-[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650582-66-4 CAPLUS

CN Piperazinone, 6-[[[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-4-methyl-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650582-67-5 CAPLUS

CN Piperazinone, 6-[[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-1,4-dimethyl-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650582-68-6 CAPLUS

CN Piperazinone, 6-[[[4-(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl-, (6*S*)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 650582-95-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5b,6aa)-octahydro-2-(1-methylethyl)cyclopenta[c]pyrrol-5-yl]methoxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650582-96-0 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5b,6aa)-octahydro-2-(1-methylethyl)cyclopenta[c]pyrrol-5-yl)methoxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650582-97-1 CAPLUS

CN Cyclopenta[c]pyrrole, 2-acetyl-5-[[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]octahydro-, (3aa,5b,6aa)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650582-98-2 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-
[[(3aa,5β,6aa)-octahydrocyclopenta[c]pyrrol-5-yl]methoxy]-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650582-99-3 CAPLUS

CN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 5-[[[4-[(4-bromo-3-chloro-2-
fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-, ethyl
ester, (3aa,5β,6aa)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650583-00-9 CAPLUS

CN Cyclopentenyl[c]pyrrole, 5-[[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]octahydro-2-(methylsulfonyl)-, (3aa,5b,6aa)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650583-01-0 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-7-[[[3aa,5b,6aa]-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy]-6-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650583-02-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-
[(3aa,5b,6aa)-octahydro-2-(2-methylpropyl)cyclopenta[c]pyrrol-5-yl]methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650583-03-2 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-7-
[(3aa,5b,6aa)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methoxy]-6-methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650583-04-3 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5β,6aa)-octahydro-2-(2-methylpropyl)cyclopenta[c]pyrrol-5-yl]methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 650583-08-7 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650583-09-8 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-phenyl-4-thiazolyl)methoxy]- (CA INDEX NAME)




RN 650583-10-1 CAPLUS
CN 4-Quinazolinamine, 7-(2,1,3-benzothiadiazol-4-ylmethoxy)-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650583-11-2 CAPLUS
CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-methyl-3-isoxazolyl)methoxy]- (CA INDEX NAME)




RN 650583-12-3 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[{(5-methyl-4-phenyl-3-isoxazolyl)methoxy]- (CA INDEX NAME)




RN 650583-13-4 CAPLUS
 CN 4-Quinazolinamine, 7-(2-benzothiazolylmethoxy)-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650583-14-5 CAPLUS
 CN 4-Quinazolinamine, 7-(2,1,3-benzoxadiazol-5-ylmethoxy)-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650583-15-6 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-(2-thienyl)-4-thiazolyl)methoxy]- (CA INDEX NAME)



RN 650583-16-7 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(1-phenyl-1H-pyrazol-4-yl)methoxy]- (CA INDEX NAME)




RN 650583-17-8 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)




RN 650583-18-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(5-[4-(trifluoromethyl)phenyl]1,2,4-oxadiazol-3-yl)methoxy]- (CA INDEX NAME)




RN 650583-19-0 CAPLUS

CN 4-Quinazolinamine, 7-[(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650583-21-4 CAPLUS


CN 4-Quinazolinamine, 7-[(6-chloro-3-pyridinyl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650583-22-5 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-(4-pyridinylmethoxy)-
 (CA INDEX NAME)




RN 650583-23-6 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-
 (CA INDEX NAME)




RN 650583-24-7 CAPLUS
 CN 4-Quinazolinamine, 7-[(6-chloro-4H-1,3-benzodioxin-8-yl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy-
 (CA INDEX NAME)



RN 650583-25-8 CAPLUS
 CN 4-Quinazolinamine, 7-[(5-chloro-1-methyl-3-phenyl-1H-pyrazol-4-yl)methoxy]-
 N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650583-26-9 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[1-methyl-3-(trifluoromethyl)-1H-thieno[2,3-c]pyrazol-5-yl]methoxy]- (CA INDEX NAME)




RN 650583-27-0 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(3-phenyl-5-isoxazolyl)methoxy]- (CA INDEX NAME)



RN 650583-29-2 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[3-(4-methoxyphenyl)-5-isoxazolyl]methoxy]- (CA INDEX NAME)



RN 650583-30-5 CAPLUS


CN 4-Quinazolinamine, 7-[{5-(2,4-dichlorophenoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methoxy]-N-(3,4-dichlorophenyl)-6-

methoxy- (CA INDEX NAME)




RN 650583-32-7 CAPLUS

CN 4-Quinazolinamine, 7-[4-(butylhexahydro-1,4-oxazepin-2-yl)methoxy]-N-(3,4-dichlorophenyl)-6-methoxy- (CA INDEX NAME)




RN 650583-34-9 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-4-pentyl-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)




RN 650583-35-0 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-4-[(tetrahydro-2H-pyran-2-yl)methyl]-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650583-36-1 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(hexahydro-4-(3-thienylmethyl)-1,4-oxazepin-2-yl)methoxy]-6-methoxy- (CA INDEX NAME)



RN 650583-37-2 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[(2R,5S,6S)-5,6-dimethyl-2-morpholinyl]methoxy]-6-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650583-38-3 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2R,5S,6S)-4,5,6-trimethyl-2-morpholinyl]methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 650583-39-4 CAPLUS


CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(2S,5S,6S)-4,5,6-trimethyl-2-morpholinyl]methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 650583-40-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-[(4,5,5-trimethyl-2-morpholinyl)methoxy]- (CA INDEX NAME)




RN 650583-62-3 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-7-[{[hexahydro-4-[(tetrahydro-2-furanyl)methyl]-1,4-oxazepin-2-yl]methoxy}-6-methoxy- (CA INDEX NAME)



RN 651031-01-5 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-
 [[(3aa,5a,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-
 yl]methoxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 651031-02-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5a,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 651031-03-7 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-6-methoxy-7-[(3aa,5a,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 651031-04-8 CAPLUS

CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5a,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 651031-05-9 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-6-methoxy-7-[(3aa,5a,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 651031-06-0 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-6-methoxy-7-
 [[(3aa,5a,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-
 yl]methoxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 651031-07-1 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-
 [[(3aa,5a,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-
 yl]methoxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 651031-08-2 CAPLUS

CN Cyclopenta[c]pyrrole, 2-acetyl-5-[[[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]octahydro-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 732983-39-0 CAPLUS


CN 4-Quinazolinamine, N-(4,5-dichloro-2-fluorophenyl)-6-methoxy-7-[[3aa,5β,6aa]-octahydro-2-methylcyclopenta[c]pyrrol-5-yl]methoxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 752201-22-2 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2,3-dichlorophenyl)-6-methoxy-7-
 [[(3ac,5β,6αa)-octahydro-2-methylcyclopenta[c]pyrrol-5-
 yl]methoxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 756475-26-0 CAPLUS
 CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[2-[(3-endo)-8-
 methyl-8-azabicyclo[3.2.1]oct-3-yl]ethoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 756816-98-5 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-
[[(3aR,6aS)-octahydro-2-methylcyclopenta[c]pyrrol-5-ylmethoxy]-, rel-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 772338-00-8 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-5-chloro-2-fluorophenyl)-6-methoxy-7-
[[(3aa,5b,6aa)-octahydro-2-methylcyclopenta[c]pyrrol-5-
yl]methoxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 778574-40-6 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-2,4-difluorophenyl)-6-methoxy-7-
[[3aa,5beta,6aa]-octahydro-2-methylcyclopenta[c]pyrrol-5-
yl]methoxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 781613-23-8 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-
[[3aa,5beta,6aa]-octahydro-2-methylcyclopenta[c]pyrrol-5-
yl]methoxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 785775-35-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-
[[3aa,5b,6aa]-octahydro-2-methylcyclopenta[c]pyrrol-5-
ylyl]methoxy]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 787547-48-2 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[(3-endo)-8-methyl-
8-azabicyclo[3.2.1]oct-3-yl]methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 650578-27-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolines as ephrin and EGFR receptor kinase modulators
for treating cancer and other disorders)

RN 650578-27-1 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-
[[(3ac,5b,6aa)-octahydrocyclopenta[c]pyrrol-5-yl)methoxy]-
, hydrobromide (9CI) (CA INDEX NAME)

Relative stereochemistry.



● x HBr

IT 650578-14-6P 650578-17-9P 650578-21-5P

650578-22-6P 650578-66-8P 650578-73-7P

650578-74-8P 650579-39-8P 650579-74-1P

650579-83-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of quinazolines as ephrin and EGFR receptor kinase modulators
for treating cancer and other disorders)

RN 650578-14-6 CAPLUS

CN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 5-[[[4-[(4-bromo-3-chloro-2-
fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-,

1,1-dimethylethyl ester, (3 α ,5 β ,6 $\alpha\alpha$)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650578-17-9 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-3-chloro-2-fluorophenyl)-6-methoxy-7-[[3 α ,5 β ,6 $\alpha\alpha$]-octahydrocyclopenta[c]pyrrol-5-ylmethoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 650578-21-5 CAPLUS

CN Cyclopenta[c]pyrrole-2(1H)-carboxylic acid, 5-[[[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]hexahydro-, 1,1-dimethylethyl ester, (3 α ,5 β ,6 $\alpha\alpha$)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650578-22-6 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-
[(3aa,5β,6aa)-octahydrocyclopenta[c]pyrrol-5-ylmethoxy]-
, hydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 650578-66-8 CAPLUS

CN 4-Quinazolinamine, 7-[{3-endo)-8-azabicyclo[3.2.1]oct-3-ylmethoxy]-N-(3,4-
dichlorophenyl)-6-methoxy-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● x HCl

RN 650578-73-7 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[2-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl)oxylethyl]-, 1,1-dimethylethyl ester, (3-endo)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 650578-74-8 CAPLUS


CN 4-Quinazolinamine, 7-[2-(3-endo)-8-azabicyclo[3.2.1]oct-3-yethoxy]-N-(3,4-dichlorophenyl)-6-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 650579-39-8 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 650579-74-1 CAPLUS

CN 4-Quinazolinamine, N-(3,4-dichlorophenyl)-6-methoxy-7-[[3-(1-piperazinyl)-1,2,4-oxadiazol-5-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 650579-83-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[(4-[(3,4-dichlorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)methyl]-2-thiazolyl]-, 1,1-dimethylethyl ester
 (CA INDEX NAME)



L4 ANSWER 7 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:41281 CAPLUS
 DOCUMENT NUMBER: 140:94060
 TITLE: Preparation of benzodioxole-containing quinazolines with MAP kinase inhibitory activity for treatment of cancer
 INVENTOR(S): Hennequin, Laurent Francois Andre; Foote, Kevin Michael; Gibson, Keith Hopkinson
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 173 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004732	A1	20040115	WO 2003-GB2874	20030704 <--
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003281193	A1	20040123	AU 2003-281193	20030704 <--
EP 1528925	A1	20050511	EP 2003-740769	20030704 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005536486	T	20051202	JP 2004-518954	20030704 <--
US 2005250797	A1	20051110	US 2005-520266	20050106 <--
PRIORITY APPLN. INFO.:			GB 2002-15825	A 20020709 <--
			GB 2003-12897	A 20030605
			WO 2003-GB2874	W 20030704

OTHER SOURCE(S): MARPAT 140:94060
 IT 643084-66-6P, N-[5-Chloro-7-(3-methoxy-1-propyn-1-yl)-1,3-

benzodioxol-4-yl]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine 643084-68-8P, N-[5-Chloro-7-(3-methoxy-1-propyn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-[2-(morpholin-4-yl)ethoxy]quinazolin-4-amine 643085-01-2P, N-[5-Chloro-7-(3-methoxy-1-propyn-1-yl)-1,3-benzodioxol-4-yl]-6-methoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]quinazolin-4-amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of benzodioxole-containing quinazolines with

MAP

kinase inhibitory activity for treatment of cancer)


RN 643084-66-6 CAPLUS

CN 4-Quinazolinamine, N-[5-chloro-7-(3-methoxy-1-propynyl)-1,3-benzodioxol-4-yl]-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (9CI) (CA INDEX NAME)




RN 643084-68-8 CAPLUS

CN 4-Quinazolinamine, N-[5-chloro-7-(3-methoxy-1-propynyl)-1,3-benzodioxol-4-yl]-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 643085-01-2 CAPLUS

CN 4-Quinazolinamine, N-[5-chloro-7-(3-methoxy-1-propynyl)-1,3-benzodioxol-4-yl]-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:41213 CAPLUS
 DOCUMENT NUMBER: 140:105249
 TITLE: Combination of mTOR inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
 INVENTOR(S): Neel, Benjamin G.; Mohi, Golam
 PATENT ASSIGNEE(S): Beth Israel Deaconess Medical Center, USA
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004644	A2	20040115	WO 2003-US20972	20030703 <--
WO 2004004644	A3	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003248813	A1	20040123	AU 2003-248813	20030703 <--
US 2006094674	A1	20060504	US 2005-520225	20051110 <--
PRIORITY APPLN. INFO.:			US 2002-394029P	P 20020705 <--
			US 2002-412402P	P 20020920
			WO 2003-US20972	W 20030703


IT 257938-36-6, ZD4190 443913-73-3, ZD6474
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination of mTOR inhibitor and tyrosine kinase inhibitor for cancer therapy)

RN 257938-36-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 443913-73-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



L4 ANSWER 9 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:1007104 CAPLUS
 DOCUMENT NUMBER: 140:35931
 TITLE: Methods for treatment of acute lymphocytic leukemia
 INVENTOR(S): Grupp, Stephan A.; Brown, Valerie I.
 PATENT ASSIGNEE(S): The Children's Hospital of Philadelphia, USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106622	A2	20031224	WO 2003-US17552	20030530 <--
WO 2003106622	A3	20040701		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003247483 A1 20031231 AU 2003-247483 20030530 <--
 US 2004039010 A1 20040226 US 2003-453056 20030530 <--
 US 7026330 B2 20060411
PRIORITY APPLN. INFO.: US 2002-384245P P 20020530 <--
 WO 2003-US17552 W 20030530

IT 443913-73-3, ZD6474
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (methods for treatment of acute lymphocytic leukemia)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




L4 ANSWER 10 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:855697 CAPLUS
 DOCUMENT NUMBER: 139:364941
 TITLE: Preparation of 3,4-diaminocyclobutene-1,2-diones as
 CXC chemokine receptor antagonists
 INVENTOR(S): Taveras, Arthur G.; Aki, Cynthia J.; Bond, Richard W.;
 Chao, Jianping; Dwyer, Michael; Ferreira, Johan A.;
 Pachter, Jonathan A.; Baldwin, John J.; Kaiser, Bernd;
 Li, Ge; Merritt, J. Robert; Nelson, Kingsley H.;
 Rokosz, Laura L.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 127 pp., Cont.-in-part of U.S.
 Ser. No. 62,006.
 DOCUMENT TYPE: CODEN: USXXCO
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003204085	A1	20031030	US 2002-208426	20020730 <--
US 2003097004	A1	20030522	US 2002-62006	20020201 <--

US 2004235908	A1	20041125	US 2004-869189	20040616 <--
PRIORITY APPLN. INFO.:			US 2001-265951P	P 20010202 <--
			US 2002-62006	A2 20020201 <--
			US 2002-208426	A3 20020730


OTHER SOURCE(S): MARPAT 139:364941
IT 443913-73-3, Zd-6474
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of 3,4-diaminocyclobutene-1,2-diones as CXC
chemokine receptor antagonists)
RN 443913-73-3 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-
piperidinyl)methoxy]- (CA INDEX NAME)



L4 ANSWER 11 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:737931 CAPLUS
DOCUMENT NUMBER: 139:255332
TITLE: Method for selecting antitumor drug sensitivity-determining factors and method for predicting antitumor drug sensitivity using the selected factors
INVENTOR(S): Aoki, Yuko; Hasegawa, Kiyoshi; Ishii, Nobuya; Mori, Kazushige
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076660	A1	20030918	WO 2002-JP2354	20020313 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NC, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2478640 A1 20030918 CA 2002-2478640 20020313 <--
 AU 2002238874 A1 20030922 AU 2002-238874 20020313 <--
 EP 1483401 A1 20041208 EP 2002-705127 20020313 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 LV, SI, LT, LV, FI, RO, MK, CY, AL, TR
 CN 1625602 A 20050608 CN 2002-828958 20020313 <--
 JP 2005519610 T 20050707 JP 2003-574857 20020313 <--
 US 2005118600 A1 20050602 US 2005-507389 20050120 <--
 PRIORITY APPLN. INFO.: WO 2002-JP2354 W 20020313 <--
 IT 443913-73-3, ZD64/4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (method for selecting antitumor drug sensitivity-determining factors and
 predicting antitumor drug sensitivity using the selected factors)
 RN 443913-73-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-
 piperidinyl)methoxy]-(CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:719299 CAPLUS
 DOCUMENT NUMBER: 139:240339
 TITLE: Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
 INVENTOR(S): Wakabayashi, Toshiaki; Ono, Naoto; Semba, Taro;
 Haneda, Toru
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003074045	A1	20030912	WO 2003-JP2492	20030304 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,			


PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,UG,US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2003211594 A1 20030916 AU 2003-211594 20030304 << EP 1481678 A1 20041201 EP 2003-743594 20030304 <<	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
US 2005119303 A1 20050602 US 2004-504676 20040813 << PRIORITY APPLN. INFO.: JP 2002-59471 A 20020305 << WO 2003-JE2492 W 20030304	

OTHER SOURCE(S): MARPAT 139:240339
IT 257938-36-6, ZD4190 443913-73-3, ZD6474
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antitumor agent comprising combination of sulfonamide-containing
heterocyclic compound with angiogenesis inhibitora)
RN 257938-36-6 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-
triazol-1-yl)ethoxy-, hydrochloride (1:1) (CA INDEX NAME)



• HCl

RN 443913-73-3 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:551500 CAPLUS
 DOCUMENT NUMBER: 139:117431
 TITLE: 4,5-Diamino-1,2,3,4-tetrahydro-3,6-pyridazinediones as CXC chemokine receptor antagonists for treatment of inflammatory disorders and cancer
 INVENTOR(S): Taveras, Arthur G.; Dwyer, Michael; Chao, Jianping; Baldwin, John J.; Merritt, Robert J.; Li, Ge; Chao, Jianhua; Yu, Younong
 PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
 SOURCE: PCT Int. Appl., 210 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057676	A1	20030717	WO 2003-US299	20030103 <--
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004063709	A1	20040401	US 2003-335789	20030102 <--
US 6878709	B2	20050412		
CA 2472165	A1	20030717	CA 2003-2472165	20030103 <--
AU 2003207460	A1	20030724	AU 2003-207460	20030103 <--
EP 1461321	A1	20040929	EP 2003-705667	20030103 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1582280	A	20050216	CN 2003-801923	20030103 <--
JP 200516029	T	20050602	JP 2003-557993	20030103 <--
MX 2004PA06555	A	20041004	MX 2004-PA6555	20040702 <--
PRIORITY APPLN. INFO.:			US 2002-346248P	P 20020104 <--
			US 2003-335789	A 20030102

OTHER SOURCE(S): MARPAT 139:117431
 IT 443913-73-3, ZD 6474
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy; preparation of pyridazinediones as CXC chemokine
 receptor antagonists for treatment of inflammatory disorders and
 cancer)
 RN 443913-73-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-
 piperidinyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:532545 CAPLUS
 DOCUMENT NUMBER: 139:95455
 TITLE: Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors
 INVENTOR(S): Geroni, Maria Cristina; Fowst, Camilla; Cozzi, Paolo
 PATENT ASSIGNEE(S): Pharmacia Italia SpA, Italy
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055522	A1	20030710	WO 2002-EP13092	20021218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472008	A1	20030710	CA 2002-2472008	20021218 <--
AU 2002352090	A1	20030715	AU 2002-352090	20021218 <--

EP 1461083	A1	20040929	EP 2002-787763	20021218 <--
EP 1461083	B1	20060329		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015454	A	20041123	BR 2002-15454	20021218 <--
HU 2004002639	A2	20050428	HU 2004-2639	20021218 <--
CN 1617744	A	20050518	CN 2002-827674	20021218 <--
JP 2005516025	T	20050602	JP 2003-556098	20021218 <--
AT 321572	T	20060415	AT 2002-787763	20021218 <--
PT 1461083	T	20060831	PT 2002-787763	20021218 <--
ES 2263835	T3	20061216	ES 2002-787763	20021218 <--
NZ 533854	A	20070531	NZ 2002-533854	20021218 <--
MX 2004PA06543	A	20041004	MX 2004-PA6543	20040702 <--
ZA 2004005290	A	20050617	ZA 2004-5290	20040702 <--
NO 2004003217	A	20040730	NO 2004-3217	20040729 <--
US 2006084612	A1	20060420	US 2005-500606	20050505 <--
IN 2007DN00991	A	20070803	IN 2007-DN991	20070206 <--
PRIORITY APPLN. INFO.:			EP 2002-75052	A 20020102 <--
			WO 2002-EPI3092	W 20021218
			IN 2004-DN1960	A3 20040708


OTHER SOURCE(S): MARPAT 139:95455

IT 443913-73-3, ZD 6474

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined antitumor therapy comprising acryloyl distamycin derivs. and
protein kinase (serine/threonine kinase) inhibitors)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:434346 CAPLUS

DOCUMENT NUMBER: 139:22222

TITLE: Preparation of arylamino-methoxyquinazolines for the prevention or treatment of T cell-mediated diseases

INVENTOR(S): Moore, Nelly Corine; Oldham, Keith

PATENT ASSIGNEE(S): Astrazeneca A.B., Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045364	A2	20030605	WO 2002-GB5217	20021120 <--
WO 2003045364	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002339194	A1	20030610	AU 2002-339194	20021120 <--
EP 1453492	A2	20040908	EP 2002-777571	20021120 <--
EP 1453492	B1	20070124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
AT 352295	T	20070215	AT 2002-777571	20021120 <--
US 2005014773	A1	20050120	US 2004-496464	20040524 <--
US 7157467	B2	20070102		
PRIORITY APPLN. INFO.:			GB 2001-28109 WO 2002-GB5217	A 20011123 <-- W 20021120


OTHER SOURCE(S): MARPAT 139:2222

- IT 401811-09-4P 401811-16-3P, 6-Methoxy-7-[N-tert-butoxycarbonylpiperidin-4-ylmethoxy]-4-[(6-chloro-2,3-methylenedioxyphenyl)amino]quinazoline 401811-35-6P, 7-[2-(4-Hydroxypiperidin-4-yl)ethoxy]-6-methoxy-4-[(2,3-methylenedioxyphenyl)amino]quinazoline
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of arylamino-methoxyquinazolines for the prevention or treatment of T cell-mediated diseases)
- RN 401811-09-4 CAPLUS
- CN 1-Piperidinecarboxylic acid, 4-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-4-hydroxy-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 401811-16-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 401811-35-6 CAPLUS

CN 4-Piperidinol, 4-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]- (CA INDEX NAME)




IT 401810-62-6P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-[(2,3-methylenedioxyphenyl)amino]quinazoline dihydrochloride
 401810-69-3P, 6-Methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-4-[(6-chloro-2,3-methylenedioxyphenyl)amino]quinazoline dihydrochloride
 401810-81-9P, 6-Methoxy-7-[(piperidin-4-yl)methoxy]-4-[(2,3-methylenedioxyphenyl)amino]quinazoline hydrochloride 401810-82-0P
 , 6-Methoxy-7-[(2-piperidin-4-yl)ethoxy]-4-[(2,3-methylenedioxyphenyl)amino]quinazoline hydrochloride 401810-83-1P
 , 6-Methoxy-7-[(1-methoxyethoxy)piperidin-4-yl)methoxy]-4-[(2,3-methylenedioxyphenyl)amino]quinazoline hydrochloride 401810-88-6P
 , 4-[(6-Chloro-2,3-methylenedioxyphenyl)amino]-6-methoxy-7-[2-pyrrolidinyl]ethoxy]quinazoline 401810-94-4P,
 6-Methoxy-7-[(2-4-methylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxyphenyl)amino]quinazoline 401810-95-5P,
 6-Methoxy-7-[(2-piperidinoethoxy)piperidin-4-yl)methoxy]-4-[(6-chloro-2,3-methylenedioxyphenyl)amino]quinazoline 401810-96-6P,
 6-Methoxy-7-[(2-4-methylpiperazin-1-yl)ethoxy]-4-[(6-chloro-2,3-methylenedioxyphenyl)amino]quinazoline 401810-97-7P,
 6-Methoxy-7-[(2-oxopyrrolidin-1-yl)ethoxy]-4-[(6-chloro-2,3-methylenedioxyphenyl)amino]quinazoline 401811-07-2P,
 6-Methoxy-7-[(2-cyanopyridin-4-yl)methoxy]-4-[(6-chloro-2,3-methylenedioxyphenyl)amino]quinazoline 401811-08-3P,
 6-Methoxy-7-[(2-cyanopyridin-4-yl)methoxy]-4-[(2,3-methylenedioxyphenyl)amino]quinazoline 401811-10-7P,
 6-Methoxy-7-[(2-(4-hydroxytetrahydropyran-4-yl)ethoxy]-4-[(2,3-methylenedioxyphenyl)amino]quinazoline 401811-11-8P,
 6-Methoxy-7-[(2-(4-hydroxytetrahydropyran-4-yl)ethoxy]-4-[(6-chloro-2,3-methylenedioxyphenyl)amino]quinazoline 401811-22-1P,
 7-[2-Homopiperidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl)amino]-6-methoxyquinazoline 401811-23-2P, 6-Methoxy-7-[2-pyrrolidinyl]ethoxy]-4-[(2,3-methylenedioxyphenyl)amino]quinazoline 401811-24-3P, 6-Methoxy-7-[(2-piperidinoethoxy)-4-[(2,3-

methyleneedioxyphenyl]amino]quinazoline 401811-36-7P,
7-[2-[4-Hydroxy-N-methylpiperidin-4-yl]ethoxy]-6-methoxy-4-[(2,3-methylenedioxyphenyl]amino]quinazoline 401811-37-8P,
4-[(6-Chloro-2,3-methylenedioxyphenyl]amino)-6-methoxy-7-[piperidin-4-ylmethoxy]quinazoline dihydrochloride 401811-38-9P,
4-[(6-Chloro-2,3-methylenedioxyphenyl]amino)-7-[N-cyanomethylpiperidin-4-ylmethoxy]-6-methoxyquinazoline 401811-61-8P,
6-Methoxy-7-[2-[5-methyl-2-morpholinomethylimidazol-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline 401811-62-9P,
(S)-6-Methoxy-7-[2-[2-[N,N-dimethylcarbamoyl]pyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline 401811-63-0P,
(S)-6-Methoxy-7-[2-[2-[N-methylcarbamoyl]pyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401811-64-1P, (S)-6-Methoxy-7-[2-[2-carbamoylpyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401811-65-2P, (S)-6-Methoxy-7-[2-[2-piperidinocarbonylpyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401811-66-3P, (S)-6-Methoxy-7-[2-[2-morpholinocarbonylpyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401811-68-5P, (S)-6-Methoxy-7-[2-[2-pyrrolidin-1-ylcarbonyl]pyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401811-69-6P, (R)-6-Methoxy-7-[2-[2-methylpyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401811-70-9P, (S)-6-Methoxy-7-[2-[2-methoxymethylpyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401811-71-0P, 6-Methoxy-7-[3-pyridylmethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401811-72-1P, 6-Methoxy-7-[4-pyridylmethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
401812-23-5P, 6-Methoxy-4-[(2,3-methylenedioxyphenyl]amino)-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline 401812-29-1P,
6-Methoxy-4-[(2,3-methylenedioxyphenyl]amino)-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline 401812-31-5P, 6-Methoxy-4-[(2,3-methylenedioxyphenyl]amino)-7-[3-pyridylmethoxy]quinazoline
401812-32-6P, 4-[(6-Chloro-2,3-methylenedioxyphenyl]amino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
537040-19-0P, 6-Methoxy-7-[2-(1-methylpiperidin-4-yl)methoxy]quinazoline dihydrochloride
537040-21-4P, 6-Methoxy-7-[2-[pyrrolidyl]ethoxy]-4-[(6-chloro-2,3-methylenedioxyphenyl]amino]quinazoline 537040-23-6P,
(S)-6-Methoxy-7-[2-[2-[4-methylpiperazin-1-ylcarbonyl]pyrrolidin-1-yl]ethoxy]-4-[(2,3-methylenedioxyphenyl]amino]quinazoline dihydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of arylamino-methoxyquinazolines for the prevention or treatment of T cell-mediated diseases)

RN 401810-62-6 CAPLUS


CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 401810-69-3 CAPLUS


CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 401810-81-9 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-(4-piperidinylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 401810-82-0 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(4-piperidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 401810-83-1 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 401810-88-6 CAPLUS
CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 401810-94-4 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 401810-95-5 CAPLUS
CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 401810-96-6 CAPLUS
CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 401810-97-7 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[(4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxy-7-quinazolinyl)oxy]ethyl]- (CA INDEX NAME)




RN 401811-07-2 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[4-((5-chloro-1,3-benzodioxol-4-yl)amino)-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)




RN 401811-08-3 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)




RN 401811-10-7 CAPLUS


CN 2H-Pyran-4-ol, 4-[2-[[4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl]oxy]ethyl]tetrahydro- (CA INDEX NAME)




RN 401811-11-8 CAPLUS
CN 2H-Pyran-4-ol, 4-[2-[(4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]tetrahydro- (CA INDEX NAME)




RN 401811-22-1 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-7-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-6-methoxy- (CA INDEX NAME)




RN 401811-23-2 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 401811-24-3 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 401811-36-7 CAPLUS
 CN 4-Piperidinol, 4-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-1-methyl- (CA INDEX NAME)




RN 401811-37-8 CAPLUS
 CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(4-piperidinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



●₂ HCl


RN 401811-38-9 CAPLUS

CN 1-Piperidineacetonitrile, 4-[(4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxy-7-quinazolinyl)oxy]methyl- (CA INDEX NAME)



RN 401811-61-8 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-[5-methyl-2-(4-morpholinylmethyl)-1H-imidazol-1-yl]ethoxy]- (CA INDEX NAME)




RN 401811-62-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-

quinazolinyl]oxy]ethyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 401811-63-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-N-methyl-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 401811-64-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 401811-65-2 CAPLUS

CN Piperidine, 1-[(2S)-1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-2-pyrrolidinyl]carbonyl-, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 401811-66-3 CAPLUS

CN Morpholine, 4-[(2S)-1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-2-pyrrolidinyl]carbonyl-, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 401811-68-5 CAPLUS

CN Pyrrolidine, 1-[(2S)-1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-2-pyrrolidinyl]carbonyl-, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 401811-69-6 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-[(2R)-2-methyl-1-pyrrolidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 401811-70-9 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 401811-71-0 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-(3-pyridinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 401811-72-1 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-(4-pyridinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 401812-23-5 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[1-(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 401812-29-1 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 401812-31-5 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-(3-pyridinylmethoxy)-
(CA INDEX NAME)



RN 401812-32-6 CAPLUS
CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[(1-
methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 537040-19-0 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(1-methyl-4-
piperidinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 537040-21-4 CAPLUS
 CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[2-(1H-pyrrol-1-yl)ethoxy]- (CA INDEX NAME)



RN 537040-23-6 CAPLUS
 CN Piperazine, 1-[(2S)-1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl]oxy]ethyl]-2-pyrrolidinyl]carbonyl]-4-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




● 2 HCl

- IT 537040-22-5, 4-[(6-Chloro-2,3-methylenedioxyphenyl)amino]-6-methoxy-7-(piperidin-4-ylmethoxy)quinazoline
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of arylamino-methoxyquinazolines for the prevention or treatment of T cell-mediated diseases)
- RN 537040-22-5 CAPLUS
- CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




- IT 401812-09-7P, (R)-7-[2,3-Epoxypropoxy]-6-methoxy-4-[(2,3-methylenedioxyphenyl)amino]quinazoline 401812-10-0P,
 (R)-4-[(6-Chloro-2,3-methylenedioxyphenyl)amino]-7-[2,3-epoxypropoxy]-6-methoxyquinazoline
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of arylamino-methoxyquinazolines for the prevention or treatment of T cell-mediated diseases)
- RN 401812-09-7 CAPLUS
- CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 401812-10-0 CAPLUS
- CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:376644 CAPLUS
 DOCUMENT NUMBER: 138:379206
 TITLE: Combination cancer therapy comprising ZD6474 and a taxane
 INVENTOR(S): Wedge, Stephen Robert
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039551	A1	20030515	WO 2002-GB5021	20021106 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2464758	A1	20030515	CA 2002-2464758	20021106 <--
AU 2002337382	A1	20030519	AU 2002-337382	20021106 <--
EP 1446124	A1	20040818	EP 2002-772624	20021106 <--
EP 1446124	B1	20060809		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013906	A	20040831	BR 2002-13906	20021106 <--
JP 2005511597	T	20050428	JP 2003-541842	20021106 <--
CN 1612738	A	20050504	CN 2002-826795	20021106 <--
AT 335488	T	20060915	AT 2002-772624	20021106 <--
NZ 532525	A	20061130	NZ 2002-532525	20021106 <--
ES 2269769	T3	20070401	ES 2002-772624	20021106 <--
ZA 2004003455	A	20050829	ZA 2004-3455	20040506 <--
MX 2004PA04355	A	20040811	MX 2004-PA4355	20040507 <--
NO 2004002365	A	20040607	NO 2004-2365	20040607 <--
US 2005043395	A1	20050224	US 2004-494704	20041019 <--
HK 1068546	A1	20070105	HK 2005-100883	20050203 <--

PRIORITY APPLN. INFO.:

GB 2001-26879

A 20011108 <--

WO 2002-GB5021

W 20021106


IT 443913-73-3P, ZD 6474

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(ZD6474-taxane combination for cancer therapy)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




IT 338992-12-4P 338992-20-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(ZD6474-taxane combination for cancer therapy)


RN 338992-12-4 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




RN 338992-20-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 338992-53-3P 524722-52-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (ZD6474-taxane combination for cancer therapy)
 RN 338992-53-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
 CM 1
 CRN 443913-73-3
 CMF C22 H24 Br F N4 O2




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 524722-52-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-

piperidinyl)methoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:355612 CAPLUS
 DOCUMENT NUMBER: 138:362649
 TITLE: Treatment of cancer with anti-ErbB2 antibodies
 INVENTOR(S): Sliwkowski, Mark X.
 PATENT ASSIGNEE(S): Genentech, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 602,812.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003086924	A1	20030508	US 2002-268501	20021010 <--
US 6949245	B1	20050927	US 2000-602812	20000623 <--
CN 101121750	A	20080213	CN 2007-10141111	20000623 <--
CN 101121021	A	20080213	CN 2007-10141112	20000623 <--
US 2004013667	A1	20040122	US 2003-608626	20030627 <--
US 2005208043	A1	20050922	US 2005-44749	20050127 <--
US 2005238640	A1	20051027	US 2005-154465	20050616 <--
US 2006034842	A1	20060216	US 2005-223361	20050909 <--
US 2006073143	A1	20060406	US 2005-222587	20050909 <--
AU 2005242195	A1	20060112	AU 2005-242195	20051207 <--
US 2006193854	A1	20060831	US 2006-429361	20060505 <--
US 2006198843	A1	20060907	US 2006-429043	20060505 <--
US 2006216285	A1	20060928	US 2006-429363	20060505 <--
US 2007184055	A1	20070809	US 2007-690691	20070323 <--
US 2007269429	A1	20071122	US 2007-770441	20070628 <--
PRIORITY APPLN. INFO.:			US 1999-141316P	P 19990625 <--
			US 2000-602812	A2 20000623 <--
			AU 2000-57632	A3 20000623 <--
			CN 2000-811898	A3 20000623 <--

US 2002-268501 A2 20021010
 US 2003-608626 A1 20030627
 US 2005-44749 A1 20050127

IT 443913-73-3, ZD6474
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (as tyrosine kinase inhibitor in combination with anti-ErbB2
 antibodies; cancer treatment with anti-ErbB2 antibodies)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



L4 ANSWER 18 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:301081 CAPLUS
 DOCUMENT NUMBER: 138:321127
 TITLE: Preparation of 3,4-disubstituted maleimide compounds
 as CXCR-chemokine receptor antagonists
 INVENTOR(S): Taveras, Arthur G.; Dwyer, Michael; Ferreira, Johan
 A.; Girijavallabhan, Viyyoor M.; Chao, Jianping;
 Baldwin, John J.; Merritt, J. Robert; Li, Ge
 PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
 SOURCE: PCT Int. Appl., 229 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031440	A1	20030417	WO 2002-US32628	20021011 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2462862	A1	20030417	CA 2002-2462862	20021011 <--
AU 2002351478	A1	20030422	AU 2002-351478	20021011 <--
US 2004034229	A1	20040219	US 2002-269775	20021011 <--

US 6903131	B2	20050607			
EP 1434775	A1	20040707	EP 2002-786395	20021011 <--	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 200550595	T	20050224	JP 2003-534423	20021011 <--	
CN 1599734	A	20050323	CN 2002-824052	20021011 <--	
MX 2004PA03439	A	20040708	MX 2004-PA3439	20040412 <--	
PRIORITY APPLN. INFO.:			US 2001-329005P	P 20011012 <--	
			WO 2002-US32628	W 20021011	


OTHER SOURCE(S): MARPAT 138:321127

IT 443913-73-3, ZD-6474

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combined with 3,4-disubstituted maleimide CXCR-chemokine receptor
antagonists useful against angiogenesis)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:102057 CAPLUS

DOCUMENT NUMBER: 138:231207

TITLE: Looking to the future: Advances in the management of hormone-refractory prostate cancer

AUTHOR(S): Trachtenberg, John; Blackledge, George

CORPORATE SOURCE: The Prostate Center, The Princess Margaret Hospital, University of Toronto, Toronto, ON, M5G 2C9, Can.

SOURCE: European Urology, Supplements (2002), 1(7), 44-53

PUBLISHER: CODEN: EUSUAU; ISSN: 1569-9056

DOCUMENT TYPE: Elsevier Science B.V.


LANGUAGE: Journal; General Review

IT 443913-73-3, ZD6474

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(management of hormone-refractory prostate cancer)

RN 443913-73-3 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:10901 CAPLUS
 DOCUMENT NUMBER: 139:483
 TITLE: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases
 AUTHOR(S): Carlomagno, Francesca; Vitagliano, Donata; Guida, Teresa; Ciardiello, Fortunato; Tortora, Giampaolo; Vecchio, Giancarlo; Ryan, Anderson J.; Fontanini, Gabriella; Fusco, Alfredo; Santoro, Massimo
 CORPORATE SOURCE: Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, Dipartimento di Biologia e Patologia Cellulare e Molecolare "Luigi Califano", University Federico II, Naples, 80131, Italy
 SOURCE: Cancer Research (2002), 62(24), 7284-7290
 CODEN: CNREA8; ISSN: 0008-5472
 PUBLISHER: American Association for Cancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 443913-73-3, ZD 6474
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases)
 RN 443913-73-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-

piperidinyl)methoxy]- (CA INDEX NAME)




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:888722 CAPLUS
 DOCUMENT NUMBER: 137:384857
 TITLE: Preparation of 4-anilinoquinazolines as antitumor agents
 INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092579	A1	20021121	WO 2002-GB2128	20020508 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002255156	A1	20021125	AU 2002-255156	20020508 <--
PRIORITY APPLN. INFO.:			EP 2001-401221	A 20010514 <--
			WO 2002-GB2128	W 20020508 <--

OTHER SOURCE(S): MARPAT 137:384857
 IT 476156-75-9P 476156-80-6P 476156-88-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-anilinoquinazolines as antitumor agents)
 RN 476156-75-9 CAPLUS
 CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 476156-80-6 CAPLUS
 CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 476156-88-4 CAPLUS
 CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 22 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:888721 CAPLUS
 DOCUMENT NUMBER: 137:384856
 TITLE: Preparation of 4-anilinoquinazolines as antitumor agents

INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092578	A1	20021121	WO 2002-GB2124	20020508 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002302736	A1	20021125	AU 2002-302736	20020508 <--
PRIORITY APPLN. INFO.:			EP 2001-401222	A 20010514 <--
			WO 2002-GB2124	W 20020508 <--


OTHER SOURCE(S): MARPAT 137:384856
 IT 476162-53-5P, 4-(2,4-Dichloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline dihydrochloride salt
 476162-54-6P 476162-56-8P 476162-58-0P
 476162-74-0P, 4-(2,4-Dichloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline 476162-76-2P,
 4-(2,4-Dichloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline 476162-77-3P, 4-(2,4-Dichloro-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline 476162-78-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-anilinoquinazolines as antitumor agents)
 RN 476162-53-5 CAPLUS
 CN 4-Quinazolinamine, N-(2,4-dichloro-5-methoxyphenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 476162-54-6 CAPLUS


CN 4-Quinazolinamine, N-(2,4-dichloro-5-methoxyphenyl)-6-methoxy-7-(4-piperidinylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 476162-56-8 CAPLUS

CN 4-Quinazolinamine, N-(2,4-dichloro-5-methoxyphenyl)-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 476162-58-0 CAPLUS
 CN 4-Quinazolinamine, N-(2,4-dichloro-5-methoxyphenyl)-6-methoxy-7-[2-(4-piperidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 476162-74-0 CAPLUS
 CN 4-Quinazolinamine, N-(2,4-dichloro-5-methoxyphenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 476162-76-2 CAPLUS

CN 4-Quinazolinamine, N-(2,4-dichloro-5-methoxyphenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 476162-77-3 CAPLUS


CN 4-Quinazolinamine, N-(2,4-dichloro-5-methoxyphenyl)-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 476162-78-4 CAPLUS

CN 4-Quinazolinamine, N-(2,4-dichloro-5-methoxyphenyl)-6-methoxy-7-[2-(4-

piperidinyl)ethoxy]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:888720 CAPLUS
DOCUMENT NUMBER: 137:384855
TITLE: Preparation of 4-anilinoquinazolines as antitumor agents
INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092577	A1	20021121	WO 2002-GB2117	20020508 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002256776	A1	20021125	AU 2002-256776	20020508 <--
PRIORITY APPLN. INFO.:			EP 2001-401223	A 20010514 <--
			WO 2002-GB2117	W 20020508 <--


OTHER SOURCE(S): MARPAT 137:384855
IT 476159-98-5P, 4-(2-Chloro-5-methoxyanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline 476159-99-6P,
4-(2-Chloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline monohydrochloride salt 476160-00-6P, 4-(2-Bromo-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline dihydrochloride salt 476160-03-9P 476160-04-0P
476160-05-1P 476160-13-1P 476160-14-2P
476160-15-3P 476160-42-6P, 4-(2-Chloro-5-methoxyanilino)-6-methoxy-7-piperidin-4-ylmethoxyquinazoline 476160-43-7P,
4-(2-Bromo-5-methoxyanilino)-6-methoxy-7-[2-(N-methylpiperidin-4-yl)ethoxy]quinazoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-anilinoquinazolines as antitumor agents)


RN 476159-98-5 CAPLUS

CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 476159-99-6 CAPLUS


CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-(4-piperidinylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 476160-00-6 CAPLUS


CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 476160-03-9 CAPLUS


CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 476160-04-0 CAPLUS

CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-6-methoxy-7-[2-(4-piperidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 476160-05-1 CAPLUS
 CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-6-methoxy-7-(4-piperidinylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 476160-13-1 CAPLUS
 CN 3-Pyridinecarbonitrile, 4-[[[4-[(2-chloro-5-methoxyphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)




RN 476160-14-2 CAPLUS
 CN 3-Pyridinecarbonitrile, 4-[[[4-[(2-bromo-5-methoxyphenyl)amino]-6-methoxy-

7-(quinazolinyl)oxy]methyl)- (CA INDEX NAME)




RN 476160-15-3 CAPLUS

CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-(2-(5-methyl-2-(4-morpholinylmethyl)-1H-imidazol-1-yl)ethoxy)- (CA INDEX NAME)




RN 476160-42-6 CAPLUS

CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




RN 476160-43-7 CAPLUS

CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)




IT 476160-46-0P, 4-(2-Chloro-5-methoxyanilino)-7-(2,3-epoxypropoxy)-6-methoxyquinazoline 476160-49-3P, 4-(2-Chloro-5-methoxyanilino)-7-((2R)-2,3-epoxypropoxy)-6-methoxyquinazoline 476160-52-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-anilinoquinazolines as antitumor agents)
RN 476160-46-0 CAPLUS
CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-(oxiranylmethoxy)- (9CI) (CA INDEX NAME)




RN 476160-49-3 CAPLUS
CN 4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 476160-52-8 CAPLUS
 CN 4-Quinazolinamine, N-(2-bromo-5-methoxyphenyl)-6-methoxy-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:754340 CAPLUS
 DOCUMENT NUMBER: 137:279205
 TITLE: Preparation of 3,4-diaminocyclobutene-1,2-diones as CXC chemokine receptor antagonists
 INVENTOR(S): Taveras, Arthur G.; Aki, Cynthia J.; Bond, Richard W.; Chao, Jianping; Dwyer, Michael; Ferreira, Johan A.; Pachter, Jonathan; Baldwin, John J.; Kaiser, Bernd; Li, Ge; Merritt, J. Robert; Nelson, Kingsley H., Jr.; Rokosz, Laura L.
 PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
 SOURCE: PCT Int. Appl., 113 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076926	A1	20021003	WO 2002-US2888	20020201 <-- W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,


CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,
 ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,
 MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK,
 SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2436351 A1 20021003 CA 2002-2436351 20020201 <--
 AU 2002303084 A1 20021008 AU 2002-303084 20020201 <--
 EP 1355875 A1 20031029 EP 2002-731085 20020201 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2002006968 A 20040309 BR 2002-6968 20020201 <--
 HU 2003004047 A2 20040428 HU 2003-4047 20020201 <--
 JP 2004529911 T 20040930 JP 2002-576189 20020201 <--
 CN 1575273 A 20050202 CN 2002-804517 20020201 <--
 NZ 527947 A 20051028 NZ 2002-527947 20020201 <--
 IN 2003CN01171 A 20050422 IN 2003-CN1171 20030729 <--
 ZA 2003005881 A 20041101 ZA 2003-5881 20030730 <--
 NO 2003003424 A 20030930 NO 2003-3424 20030731 <--
 MX 2003PA06950 A 20031118 MX 2003-PA6950 20030801 <--
 PRIORITY APPLN. INFO.: US 2001-265951P P 20010202 <--
 WO 2002-US2888 W 20020201 <--
 OTHER SOURCE(S): CASREACT 137:279205; MARPAT 137:279205
 IT 443913-73-3, Zd-6474
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of 3,4-diaminocyclobutene-1,2-diones as CXC
 chemokine receptor antagonists)
 RN 443913-73-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-
 piperidinyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:640221 CAPLUS
 DOCUMENT NUMBER: 138:198255
 TITLE: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
 AUTHOR(S): Wedge, Stephen R.; Ogilvie, Donald J.; Dukes, Michael;
 Kendrew, Jane; Chester, Rosemary; Jackson, Janet A.;
 Boffey, Sarah J.; Valentine, Paula J.; Curwen, Jon O.;

Musgrove, Helen L.; Graham, George A.; Hughes, Gareth D.; Thomas, Andrew P.; Stokes, Elaine S. E.; Curry, Brenda; Richmond, Graham H. P.; Wadsworth, Peter F.; Bigley, Alison L.; Hennequin, Laurent F.
CORPORATE SOURCE: Departments of Cancer and Infection Research, AstraZeneca, Cheshire, SK10 4TG, UK
SOURCE: Cancer Research (2002), 62(16), 4645-4655
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 443913-73-3, ZD6474
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration)
RN 443913-73-3 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:555278 CAPLUS
DOCUMENT NUMBER: 137:119643
TITLE: Methods using a combretastatin compound combined with an antitumor agent for modulating tumor growth and metastasis
INVENTOR(S): Lee, Francis Y.; Peck, Ronald; Chaplin, David; Pero, Ronald; Edvardsen, Klaus
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Oxigene, Inc.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056692	A1	20020725	WO 2001-US50261	20011220 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				


GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2432792 A1 20020725 CA 2001-2432792 20011220 <--
 AU 2002246827 A1 20020730 AU 2002-246827 20011220 <--
 EP 1351573 A1 20031015 EP 2001-994435 20011220 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004523517 T 20040805 JP 2002-557211 20011220 <--
 PRIORITY APPLN. INFO.: US 2000-258195P P 20001222 <--
 WO 2001-US50261 W 20011220 <--

IT 443913-73-3

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combreastatin compound combined with antitumor agent for modulating tumor growth and metastasis)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 20021332187 CAPLUS
 DOCUMENT NUMBER: 136:340694
 TITLE: Preparation of 4-(indol-7-ylamino)quinazolines as antitumor agents
 INVENTOR(S): Lambert, Christine Marie-Paul; Ple, Patrick
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034744	A1	20020502	WO 2001-GB4674	20011019 <--


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002012436 A5 20020506 AU 2002-12436 20011019 <--
 EP 1332141 A1 20030806 EP 2001-980640 20011019 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004512335 T 20040422 JP 2002-537735 20011019 <--
 US 2004063733 A1 20040401 US 2003-415053 20031022 <--
 PRIORITY APPLN. INFO.: EP 2000-402962 A 20001025 <--
 WO 2001-GB4674 W 20011019 <--
 OTHER SOURCE(S): MARPAT 136:340694

IT 418811-77-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of 4-(indol-7-ylamino)quinazolines as antitumor agents)

RN 418811-77-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-7-yl-6-methoxy-7-[(4-methyl-1-
 piperazinyl)methoxy]- (CA INDEX NAME)




IT 418811-66-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 4-(indol-7-ylamino)quinazolines as antitumor agents)

RN 418811-66-2 CAPLUS

CN 4-Quinazolinamine, N-(3-chloro-1H-indol-7-yl)-6-methoxy-7-[(2R)-
 oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:293648 CAPLUS
 DOCUMENT NUMBER: 136:325554
 TITLE: Preparation of 4-(4-benzofuranyl amino)quinazolines as c-Src tyrosine kinase inhibitors
 INVENTOR(S): Lambert, Christine Marie-Paul; Ple, Patrick
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030926	A1	20020418	WO 2001-GB4497	20011009 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001092137	A5	20020422	AU 2001-92137	20011009 <--
EP 1326860	A1	20030716	EP 2001-972363	20011009 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004511480	T	20040415	JP 2002-534312	20011009 <--
US 2004044015	A1	2004040304	US 2003-399017	20030410 <--
US 6939866	B2	20050906		
PRIORITY APPLN. INFO.:			EP 2000-402845 WO 2001-GB4497	A 20001013 <-- W 20011009 <--


OTHER SOURCE(S): MARPAT 136:325554
 IT 412335-81-0P 412337-01-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-(4-benzofuranyl amino)quinazolines as c-Src tyrosine kinase inhibitors)
RN 412335-81-0 CAPLUS
CN 4-Quinazolinamine, N-4-benzofuranyl-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 412337-01-0 CAPLUS
CN 4-Quinazolinamine, N-4-benzofuranyl-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:293646 CAPLUS
DOCUMENT NUMBER: 136:325553
TITLE: Preparation of 4-(7-benzofuranyl amino)quinazolines with antitumor activity
INVENTOR(S): Lambert, Christine Marie Paul; Ple, Patrick
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030924	A1	20020418	WO 2001-GB4498	20011009 <--
WO 2002030924	A9	20030522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2001092138 A5 20020422 AU 2001-92138 20011009 <--
 EP 1326859 A1 20030716 EP 2001-972364 20011009 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004511479 T 20040415 JP 2002-534310 20011009 <--
 US 2004048881 A1 20040311 US 2003-398793 20030408 <--
 US 6849625 B2 20050201
 PRIORITY APPLN. INFO.: EP 2000-402844 A 20001013 <--
 WO 2001-GB4498 W 20011009 <--
 OTHER SOURCE(S): MARPAT 136:325553

IT 412349-08-7P 412349-09-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 4-(7-benzofuranylaminoo)quinazolines with antitumor activity)
 RN 412349-08-7 CAPLUS
 CN 1-Piperidinocarboxylic acid, 4-[2-[(4-[(6-chloro-7-benzofuranyl)amino]-6-methoxy-7-quinazolinyl)oxo]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 412349-09-8 CAPLUS
 CN 4-Quinazolinamine, N-(6-chloro-7-benzofuranyl)-6-methoxy-7-[2-(4-piperidinyl)ethoxy]- (CA INDEX NAME)




IT 412348-87-9P 412348-88-0P 412348-90-4P
 412348-95-9P 412348-97-1P 412349-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-(7-benzofuranyl amino)quinazolines with antitumor activity)


RN 412348-87-9 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-7-benzofuranyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




RN 412348-88-0 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-7-benzofuranyl)-6-methoxy-7-[(4-methyl-1-piperazinyl)methoxy]- (CA INDEX NAME)




RN 412348-90-4 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-7-benzofuranyl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 412348-95-9 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-7-benzofuranyl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 412348-97-1 CAPLUS
 CN 4-Quinazolinamine, N-(6-chloro-7-benzofuranyl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 412349-47-4 CAPLUS
 CN 4-Quinazolinamine, N-7-benzofuranyl-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



IT 412349-28-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 4-(7-benzofuranylamino)quinazolines with antitumor activity)
 RN 412349-28-1 CAPLUS
 CN 4-Quinazolinamine, N-(6-chloro-7-benzofuranyl)-6-methoxy-7-(1-piperazinylmethoxy)- (CA INDEX NAME)




IT 412349-23-6P, 7-(N-tert-Butoxycarbonylpiperidin-4-ylmethoxy)-4-(6-chlorobenzofuran-7-ylamino)-6-methoxyquinazoline 412349-24-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 4-(7-benzofuranyl)amino)quinazolines with antitumor activity)
 RN 412349-23-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[4-[(6-chloro-7-benzofuranyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 412349-24-7 CAPLUS
 CN 4-Quinazolinamine, N-(6-chloro-7-benzofuranyl)-6-methoxy-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:157764 CAPLUS

DOCUMENT NUMBER: 136:200201
 TITLE: Preparation of quinazolines as an anti-invasive agent
 in the containment and/or treatment of solid tumor
 disease
 INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick;
 Lambert, Christine Marie Paul
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016352	A1	20020228	WO 2001-GB3649	20010815 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419301	A1	20020228	CA 2001-2419301	20010815 <--
AU 2001078609	A	20020304	AU 2001-78609	20010815 <--
EP 1313727	A1	20030528	EP 2001-956688	20010815 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013358	A	20030701	BR 2001-13358	20010815 <--
JP 2004506732	T	20040304	JP 2002-521453	20010815 <--
NZ 523702	A	20040827	NZ 2001-523702	20010815 <--
EE 2003000071	A	20041215	EE 2003-71	20010815 <--
RU 2267489	C2	20060110	RU 2003-107683	20010815 <--
TW 280960	B	20070511	TW 2001-90122895	20010914 <--
ZA 20030000569	A	20040421	ZA 2003-569	20030121 <--
MX 2003PA01332	A	20040708	MX 2003-PA1332	20030213 <--
US 2004034046	A1	20040219	US 2003-344678	20030214 <--
US 7115615	B2	20061003		
NO 2003000795	A	20030404	NO 2003-795	20030220 <--
PRIORITY APPLN. INFO.:			EP 2000-402320	A 20000821 <--
			EP 2001-401006	A 20010419 <--
			WO 2001-GB3649	W 20010815 <--

OTHER SOURCE(S): MARPAT 136:200201
 IT 401811-09-4P 401811-16-3P 401811-35-6P
 401811-37-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of quinazolines as an anti-invasive agent in the containment
 and/or treatment of solid tumor disease)
 RN 401811-09-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-
 methoxy-7-quinazolinyl)oxy]ethyl]-4-hydroxy-, 1,1-dimethylethyl ester (CA
 INDEX NAME)




RN 401811-16-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 401811-35-6 CAPLUS

CN 4-Piperidinol, 4-[2-[[4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 401811-37-8 CAPLUS

CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(4-piperidinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)




●₂ HCl

IT 401810-62-6P 401810-69-3P 401810-80-8P
 401810-81-9P 401810-82-0P 401810-83-1P
 401810-88-6P 401810-94-4P 401810-95-5P
 401810-96-6P 401810-97-7P 401811-07-2P
 401811-08-3P 401811-10-7P 401811-11-8P
 401811-22-1P 401811-23-2P 401811-24-3P
 401811-36-7P 401811-38-9P 401811-61-8P
 401811-62-9P 401811-63-0P 401811-64-1P
 401811-65-2P 401811-66-3P 401811-67-4P
 401811-68-5P 401811-69-6P 401811-70-9P
 401811-71-0P 401811-72-1P 401812-23-5P
 401812-29-1P 401812-31-5P 401812-32-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of quinazolines as an anti-invasive agent in the containment and/or treatment of solid tumor disease)

RN 401810-62-6 CAPLUS


CN 4-Quinazolinamine, N-(1,3-benzodioxol-4-yl-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●₂ HCl

RN 401810-69-3 CAPLUS


CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 401810-80-8 CAPLUS


CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 401810-81-9 CAPLUS


CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-(4-piperidinylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 401810-82-0 CAPLUS


CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(4-piperidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 401810-83-1 CAPLUS


CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[1-[2-(4-morpholinyl)ethyl]-4-piperidinylmethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 401810-88-6 CAPLUS

CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 401810-94-4 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 401810-95-5 CAPLUS

CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 401810-96-6 CAPLUS

CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 401810-97-7 CAPLUS

CN 2-Pyrrolidinone, 1-[2-[(4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxy-7-quinazolinyl)oxy]ethyl]- (CA INDEX NAME)




RN 401811-07-2 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[4-((5-chloro-1,3-benzodioxol-4-yl)amino)-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)




RN 401811-08-3 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[4-((1,3-benzodioxol-4-yl)amino)-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)




RN 401811-10-7 CAPLUS


CN 2H-Pyran-4-ol, 4-[2-[(4-((1,3-benzodioxol-4-yl)amino)-6-methoxy-7-quinazolinyl)oxy]ethyl]tetrahydro- (CA INDEX NAME)




RN 401811-11-8 CAPLUS
CN 2H-Pyran-4-ol, 4-[2-[(4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]tetrahydro- (CA INDEX NAME)




RN 401811-22-1 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-7-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-6-methoxy- (CA INDEX NAME)




RN 401811-23-2 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 401811-24-3 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 401811-36-7 CAPLUS
 CN 4-Piperidinol, 4-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-1-methyl- (CA INDEX NAME)




RN 401811-38-9 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)



RN 401811-61-8 CAPLUS


CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-[5-methyl-2-(4-morpholinylmethyl)-1H-imidazol-1-yl]ethoxy]- (CA INDEX NAME)



RN 401811-62-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 401811-63-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 401811-64-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 401811-65-2 CAPLUS

CN Piperidine, 1-[[[2S]-1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-2-pyrrolidinyl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 401811-66-3 CAPLUS

CN Morpholine, 4-[(2S)-1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-2-pyrrolidinyl]carbonyl-, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl


RN 401811-67-4 CAPLUS
CN Piperazine, 1-[(2S)-1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-2-pyrrolidinyl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401811-68-5 CAPLUS
CN Pyrrolidine, 1-[(2S)-1-[2-[(4-(1,3-benzodioxol-4-ylamino)-6-methoxy-7-quinazolinyl)oxy]ethyl]-2-pyrrolidinyl]carbonyl-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 401811-69-6 CAPLUS
CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-[(2R)-2-methyl-1-pyrrolidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 401811-70-9 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 401811-71-0 CAPLUS

CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-(3-pyridinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 401811-72-1 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-(4-pyridinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 401812-23-5 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 401812-29-1 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 401812-31-5 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-(3-pyridinylmethoxy)-
 (CA INDEX NAME)




RN 401812-32-6 CAPLUS
 CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




IT 401812-09-7P 401812-10-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of quinazolines as an anti-invasive agent in the containment
 and/or treatment of solid tumor disease)
 RN 401812-09-7 CAPLUS
 CN 4-Quinazolinamine, N-1,3-benzodioxol-4-yl-6-methoxy-7-[(2R)-
 oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401812-10-0 CAPLUS
 CN 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-[(2R)-oxiranylmethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:125805 CAPLUS
 DOCUMENT NUMBER: 136:325511
 TITLE: Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors
 AUTHOR(S): Hennequin, Laurent F.; Stokes, Elaine S. E.; Thomas, Andrew P.; Johnstone, Craig; Ple, Patrick A.; Ogilvie, Donald J.; Dukes, Michael; Wedge, Stephen R.; Kendrew, Jane; Curwen, Jon O.
 CORPORATE SOURCE: Centre de Recherches, AstraZeneca, Reims, 51689, Fr.
 SOURCE: Journal of Medicinal Chemistry (2002), 45(6), 1300-1312
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:325511
 IT 443913-73-3P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent)
(preparation, bioavailability, structure activity relationship and antitumor
activity of anilinoquinazoline VEGF receptor tyrosine kinase
inhibitors)

RN 443913-73-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




IT 196603-72-2

RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation, structure activity relationship and antitumor activity of anilinoquinazoline VEGF receptor tyrosine kinase inhibitors)

RN 196603-72-2 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




IT 413599-43-6P 413599-48-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation, structure activity relationship and antitumor activity of anilinoquinazoline VEGF receptor tyrosine kinase inhibitors)


RN 413599-43-6 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (5:9) (CA INDEX NAME)



● 9/5 HCl


RN 413599-48-1 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(4-piperidinyl)ethoxy]- (CA INDEX NAME)



IT 196603-60-8P 205193-43-7P 338991-97-2P
 338992-03-3P 338992-05-5P 338992-10-2P
 338992-12-4P 338992-16-8P 413599-46-9P
 413599-47-0P 413599-52-7P 413599-53-8P
 413599-54-9P 413599-55-0P 413599-57-2P
 413599-58-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, structure activity relationship and antitumor activity of anilinoquinazoline VEGF receptor tyrosine kinase inhibitors)


RN 196603-60-8 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 205193-43-7 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 338991-97-2 CAPLUS


CN 4-Quinazolinamine, N-(2-fluoro-4-methylphenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 338992-03-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2,6-difluorophenyl)-6-methoxy-7-[(1-methyl-

4-(piperidinyl)methoxy]- (CA INDEX NAME)




RN 338992-05-5 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2,6-difluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 338992-10-2 CAPLUS


CN 4-Quinazolinamine, N-(2-fluoro-4-methylphenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




RN 338992-12-4 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 338992-16-8 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2,6-difluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




RN 413599-46-9 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)-, hydrochloride (4:9) (CA INDEX NAME)




● 9/4 HCl

RN 413599-47-0 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 413599-52-7 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 413599-53-8 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 413599-54-9 CAPLUS

CN Phenol, 4-fluoro-5-[(6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl)amino]-2-methyl-, hydrochloride (20:39) (CA INDEX NAME)




● 39/20 HCl

RN 413599-55-0 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1-methyl-4-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 413599-57-2 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[[(3R)-1-methyl-3-piperidinyl]methoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 413599-58-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(3S)-1-methyl-3-piperidinyl]methoxy- (CA INDEX NAME)

Absolute stereochemistry.



IT 338992-14-6P 338992-20-4P 338992-35-1P


338992-40-8P 338992-46-4P 413599-49-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, structure activity relationship and antitumor activity of anilinoquinazoline VEGF receptor tyrosine kinase inhibitors)


RN 338992-14-6 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2,6-difluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy- (CA INDEX NAME)




RN 338992-20-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 338992-35-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2-fluoro-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 338992-40-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-bromo-2,6-difluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 338992-46-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-chloro-2,6-difluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 413599-49-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[4-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 338992-53-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, structure activity relationship and antitumor activity of

anilinoquinazoline VEGF receptor tyrosine kinase inhibitors
RN 338992-53-3 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 443913-73-3
CMF C22 H24 Br F N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 413599-62-9

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(preparation, structure activity relationship, bioavailability and antitumor activity of anilinoquinazoline VEGF receptor tyrosine kinase inhibitors)

RN 413599-62-9 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:762976 CAPLUS
 DOCUMENT NUMBER: 135:303906
 TITLE: Preparation of quinazolines useful in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal
 INVENTOR(S): Hennequin, Laurent Francois Andre; Stokes, Elaine Sophie Elizabeth
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077085	A1	20011018	WO 2001-GB1514	20010403 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2403365	A1	20011018	CA 2001-2403365	20010403 <--
BR 2001009828	A	20021217	BR 2001-9828	20010403 <--
EP 1274692	A1	20030115	EP 2001-921530	20010403 <--
EP 1274692	B1	20060802		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003530387	T	20031014	JP 2001-575560	20010403 <--
NZ 521421	A	20040924	NZ 2001-521421	20010403 <--
AU 779695	B2	20050210	AU 2001-48507	20010403 <--
AT 334973	T	20060815	AT 2001-921530	20010403 <--
ES 2267748	T3	20070316	ES 2001-921530	20010403 <--
ZA 2002007382	A	20031215	ZA 2002-7382	20020913 <--
NO 2002004763	A	20021119	NO 2002-4763	20021003 <--
NO 324471	B1	20071029		
US 2003191308	A1	20031009	US 2002-240658	20021003 <--

US 7160889	B2	20070109		
MX 2002PA09891	A	20030327	MX 2002-PA9891	20021007 <--
US 2007066633	A1	20070322	US 2006-600752	20061117 <--
PRIORITY APPLN. INFO.:			EP 2000-400967	A 20000407 <--
			EP 2000-400968	A 20000407 <--
			EP 2000-401033	A 20000413 <--
			EP 2000-401034	A 20000413 <--
			WO 2001-GB1514	W 20010403 <--
			US 2002-240658	A3 20021003

OTHER SOURCE(S): MARPAT 135:303906


IT 367272-17-1P 367272-18-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazolines useful in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal)


RN 367272-17-1 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(oxiranylmethoxy)- (9CI) (CA INDEX NAME)



RN 367272-18-2 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-(oxiranylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:747609 CAPLUS

DOCUMENT NUMBER: 135:283196


TITLE: Therapeutic combinations of antihypertensive and

INVENTOR(S): Curwen, Jon Owen; Ogilvie, Donald James
 PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
 SOURCE: PCT Int. Appl., 40 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074360	A1	20011011	WO 2001-GB1522	20010402 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2401854	A1	20011011	CA 2001-2401854	20010402 <--
EP 1272186	A1	20030108	EP 2001-917305	20010402 <--
EP 1272186	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009729	A	20030204	BR 2001-9729	20010402 <--
HU 2003000426	A2	20030628	HU 2003-426	20010402 <--
JP 2003528917	T	20030930	JP 2001-572104	20010402 <--
EE 200200578	A	20040615	EE 2002-578	20010402 <--
NZ 520938	A	20050826	NZ 2001-520938	20010402 <--
AT 355065	T	20060315	AT 2001-917305	20010402 <--
EP 1658849	A2	20060524	EP 2006-3576	20010402 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 534455	A	20070126	NZ 2001-534455	20010402 <--
EP 1790340	A2	20070530	EP 2007-3863	20010402 <--
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
ES 2280349	T3	20070916	ES 2001-917305	20010402 <--
IN 2002M01149	A	20050304	IN 2002-MN1149	20020823 <--
ZA 2002006959	A	20031201	ZA 2002-6959	20020829 <--
US 2003144298	A1	20030731	US 2002-240413	20021001 <--
MX 2002PA09743	A	20030327	MX 2002-PA9743	20021003 <--
NO 2002004814	A	20021112	NO 2002-4814	20021004 <--
NO 323467	B1	20070521		
NO 2006002050	A	20011008	NO 2006-2050	20060508 <--
PRIORITY APPLN. INFO.:			GB 2000-8269	A 20000405 <--
			EP 2001-917305	A3 20010402 <--
			NZ 2001-520938	A1 20010402 <--
			WO 2001-GB1522	W 20010402 <--

OTHER SOURCE(S): MARPAT 135:283196
 IT 443913-73-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic combinations of antihypertensive and antiangiogenic agents)
 RN 443913-73-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:338522 CAPLUS
 DOCUMENT NUMBER: 134:353317
 TITLE: Preparation of 4-anilino-7-piperidinyloxyquinazolines as vascular endothelial growth factor inhibitors.
 INVENTOR(S): Hennequin, Laurent Francois Andre; Stokes, Elaine Sophie Elizabeth; Thomas, Andrew Peter
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Ltd.
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032651	A1	20010510	WO 2000-GB4181	20001101 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TI, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2389767	A1	20010510	CA 2000-2389767	20001101 <--
BR 2000015203	A	20020716	BR 2000-15203	20001101 <--
EP 1244647	A1	20021002	EP 2000-974667	20001101 <--
EP 1244647	B1	20060621		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003513089	T	20030408	JP 2001-534802	20001101 <--
JP 3522727	B2	20040426		
HU 2002003453	A2	20030528	HU 2002-3453	20001101 <--
HU 2002003453	A3	20030728		
EE 200200237	A	20030616	EE 2002-237	20001101 <--
AU 769222	B2	20040122	AU 2001-12886	20001101 <--
NZ 518028	A	20040326	NZ 2000-518028	20001101 <--

EP 1676845	A1	20060705	EP 2006-4921	20001101 <--
R: AT, BE, CH, IE, SI, LT,	DE, DK, ES, FR, LV, FI, RO, MK,	GB, GR, IT, LI, CY, AL, TR		
AT 330954	T	20060715	AT 2000-974667	20001101 <--
PT 1244647	T	20061031	PT 2000-974667	20001101 <--
RU 2291868	C2	20070120	RU 2002-114809	20001101 <--
ES 2265998	T3	20070301	ES 2000-974667	20001101 <--
IN 2002MN00344	A	20050318	IN 2002-MN344	20020321 <--
ZA 2002002775	A	20031203	ZA 2002-2775	20020409 <--
BG 106659	A	20030331	BG 2002-106659	20020426 <--
MX 2002PA04366	A	20021107	MX 2002-PA4366	20020430 <--
NO 2002002139	A	20020503	NO 2002-2139	20020503 <--
NO 322298	B1	20060911		
US 7173038	B1	20070206	US 2002-129336	20020503 <--
HK 1049664	A1	20061110	HK 2003-101686	20030307 <--
US 2007265286	A1	20071115	US 2006-642979	20061221 <--
KR 2007104683	A	20071026	KR 2007-722543	20071002 <--
PRIORITY APPLN. INFO.:			EP 1999-402759	A 19991105 <--
			EP 1999-402877	A 19991119 <--
			EP 2000-974667	A3 20001101 <--
			WO 2000-GB4181	W 20001101 <--
			US 2002-129336	A1 20020503 <--
			KR 2002-705814	A3 20020504 <--


OTHER SOURCE(S):

MARPAT 134:353317
 IT 338991-92-7P 338991-97-2P 338992-03-3P
 338992-05-5P 338992-08-8P 338992-10-2P
 338992-12-4P 338992-14-6P 338992-16-8P
 338992-48-6P 338992-53-3P 338992-62-4P
 338992-65-7P 443913-73-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-anilino-7-piperidinyloxyquinazolines as vascular endothelial growth factor inhibitors)


RN 338991-92-7 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 338991-97-2 CAPLUS


CN 4-Quinazolinamine, N-(2-fluoro-4-methylphenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)



RN 338992-03-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2,6-difluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 338992-05-5 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2,6-difluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




RN 338992-08-8 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(4-

piperidinylmethoxy)- (CA INDEX NAME)




RN 338992-10-2 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-4-methylphenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




RN 338992-12-4 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)




RN 338992-14-6 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2,6-difluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 338992-16-8 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2,6-difluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 338992-48-6 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, hydrochloride (10:27) (CA INDEX NAME)




RN 338992-53-3 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 443913-73-3


CMF C22 H24 Br F N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 338992-62-4 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 338992-65-7 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(4-piperidinylmethoxy)-, hydrochloride (10:23) (CA INDEX NAME)



●23/10 HCl

RN 443913-73-3 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]- (CA INDEX NAME)




IT 338992-20-4P 338992-35-1P 338992-40-8P
338992-46-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-anilino-7-piperidinyloxyquinazolines as vascular endothelial growth factor inhibitors)


RN 338992-20-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 338992-35-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(2-fluoro-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 338992-40-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-bromo-2,6-difluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 338992-46-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(4-chloro-2,6-difluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:228866 CAPLUS
 DOCUMENT NUMBER: 134:266317
 TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
 INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 306 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021596	A1	20010329	WO 2000-GB3580	20000918 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384291	A1	20010329	CA 2000-2384291	20000918 <--
BR 2000014116	A	20020521	BR 2000-14116	20000918 <--
EP 1218354	A1	20020703	EP 2000-960840	20000918 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 20030509499	T	20030311	JP 2001-524975	20000918 <--
EE 200200119	A	20030415	EE 2002-119	20000918 <--
HU 2003000059	A2	20030728	HU 2003-59	20000918 <--
HU 2003000059	A3	20030828		
BG 106492	A	20030131	BG 2002-106492	20020307 <--
IN 2002MN00293	A	20050318	IN 2002-MN293	20020308 <--
ZA 2002002234	A	20030619	ZA 2002-2234	20020319 <--
NO 2002001399	A	20020430	NO 2002-1399	20020320 <--
PRIORITY APPLN. INFO.:			GB 1999-22154	A 19990921 <--
			GB 1999-22170	A 19990921 <--
			WO 2000-GB3580	W 20000918 <--
			WO 2000-GB9100	A 20000918 <--
OTHER SOURCE(S): MARPAT 134:266317				
IT 331772-53-3P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
			(preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)	
RN 331772-53-3 CAPLUS				
CN Benzanide, N-[4-[(6-methoxy-7-(2-pyrrolidinylmethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)				




IT 331772-12-4P 331772-29-3P 331772-31-7P
 331772-34-0P 331772-46-4P 331772-49-7P
 331772-54-4P 331772-55-5P 331772-56-6P
 331772-66-8P 331772-67-9P 331772-68-0P
 331772-69-1P 331772-70-4P 331772-71-5P
 331772-72-6P 331772-73-7P 331772-74-8P
 331772-95-3P 331773-34-3P 331773-37-6P
 331773-43-4P 331773-45-6P 331773-47-8P
 331773-48-9P 331773-49-0P 331773-50-3P
 331773-51-4P 331773-52-5P 331773-54-7P
 331773-56-9P 331773-57-0P 331773-58-1P
 331773-60-5P 331773-64-9P 331773-65-0P
 331773-66-1P 331773-67-2P 331773-70-7P
 331773-71-8P 331773-72-9P 331773-73-0P
 331773-74-1P 331773-75-2P 331773-76-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331772-12-4 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinyl)amino]phenyl]- (CA INDEX NAME)



RN 331772-29-3 CAPLUS


CN Benzamide, N-[4-[(6-methoxy-7-[(2-(4-morpholinyl)ethoxy]-4-

quinazolinyl]amino]phenyl)- (CA INDEX NAME)




RN 331772-31-7 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl)amino]phenyl)- (CA INDEX NAME)




RN 331772-34-0 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl)amino]phenyl)- (CA INDEX NAME)




RN 331772-46-4 CAPLUS
 CN Benzamide, N-[4-[(6-methoxy-7-[(2S)-oxiranylmethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-49-7 CAPLUS
 CN Benzamide, N-[4-[(6-methoxy-7-[(2R)-oxiranylmethoxy]-4-quinazolinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331772-54-4 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-(4-piperidinylmethoxy)-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-55-5 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-2-pyrrolidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-56-6 CAPLUS

CN Benzamide, N-[4-[(6-methoxy-7-[(1-methyl-3-pyrrolidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-66-8 CAPLUS

CN Benzamide, N-[4-[(7-[(1-(cyclopropylmethyl)-2-pyrrolidinyl]methoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-67-9 CAPLUS

CN Benzamide, N-[4-[(7-[(1-(cyclobutylmethyl)-2-pyrrolidinyl]methoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-68-0 CAPLUS

CN Benzamide, N-[4-[[7-[(1-(2-hydroxyethyl)-2-pyrrolidinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-69-1 CAPLUS

CN Benzamide, N-[4-[[7-[[1-(2-(ethylthio)ethyl]-2-pyrrolidinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-70-4 CAPLUS

CN Benzamide, N-[4-[(7-[(1-(cyclopropylmethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-71-5 CAPLUS

CN Benzamide, N-[4-[(7-[(1-(2-hydroxyethyl)-4-piperidinyl]methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-72-6 CAPLUS

CN Benzamide, N-[4-[(1-(2-methoxyethyl)-4-piperidinyl)methoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-73-7 CAPLUS


CN Benzamide, N-[4-[(1-(cyanomethyl)-4-piperidinyl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331772-74-8 CAPLUS
CN Benzanide, N-[4-[17-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




RN 331772-95-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-[2-[[4-[(4-(benzoylamino)phenyl)amino]-6-methoxy-7-quinazolinyl]oxylethyl]- (CA INDEX NAME)




RN 331773-34-3 CAPLUS
CN Benzanide, N-[4-[(6-methoxy-7-[2-(4-thiomorpholinyl)ethoxy]-4-quinazolinyl)amino]phenyl- (CA INDEX NAME)




RN 331773-37-6 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-{2-(1-piperidinyl)ethoxy}-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-43-4 CAPLUS
CN Benzamide, N-[4-[(7-{2-(hexahydro-1H-azepin-1-yl)ethoxy}-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-45-6 CAPLUS
CN Benzamide, N-[4-[(7-[2-(2,5-dihydro-1H-pyrrol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-47-8 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-48-9 CAPLUS
CN Benzamide, N-[4-[(7-[2-(4-cyclopropyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-49-0 CAPLUS


CN Benzamide, N-[4-[(7-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 331773-50-3 CAPLUS


CN Benzamide, N-[4-[(7-[(2-(4-hydroxy-1-piperidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-51-4 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[2-[4-(2-(4-morpholinyl)ethyl]-1-piperazinyl]ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-52-5 CAPLUS
CN Benzamide, N-[4-[(7-[2-[4-(3-hydroxypropyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-54-7 CAPLUS
CN Benzamide, N-[4-[(7-[2-(3-hydroxy-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-56-9 CAPLUS

CN Benzanide, N-[4-[(7-(2-[1,4'-bipiperidin]-1'-yethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-57-0 CAPLUS


CN Benzanide, N-[4-[(7-(2-(3,5-dimethyl-4-morpholinyl)ethoxy)-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-58-1 CAPLUS
CN Benzamide, N-[4-[(7-[2-(4-acetyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-60-5 CAPLUS
CN Benzamide, N-[4-[(6-methoxy-7-[2-(2-methyl-1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-64-9 CAPLUS
CN Benzamide, N-[4-[(7-[2-(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)



RN 331773-65-0 CAPLUS
 CN Benzamide, N-[4-[(7-{[2-[(4-fluorophenyl)-1-piperazinyl]ethoxy]-6-methoxy-4-quinazolinyl}amino)phenyl]- (CA INDEX NAME)




RN 331773-66-1 CAPLUS
 CN 2-Thiazolidinecarboxylic acid, 3-[2-[(4-[(benzoylamino)phenyl]amino)-6-methoxy-7-quinazolinyl]oxy]ethyl- (CA INDEX NAME)




RN 331773-67-2 CAPLUS

CN Benzamide, N-[4-[(7-[2-[4-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-70-7 CAPLUS

CN Benzamide, N-[4-[(7-[2-(2,5-dimethyl-1-pyrrolidinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-71-8 CAPLUS

CN Benzamide, N-[4-[(7-[2-(3,6-dihydro-1(2H)-pyridinyl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl]- (CA INDEX NAME)




RN 331773-72-9 CAPLUS

CN Benzanide, N-[4-[(6-methoxy-7-{2-(4-methyl-1-piperidinyl)ethoxy}-4-quinazolininyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-73-0 CAPLUS


CN Benzanide, N-[4-[(7-{2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy}-6-methoxy-4-quinazolininyl)amino]phenyl]- (CA INDEX NAME)




RN 331773-74-1 CAPLUS
CN Benzanide, N-[4-[[7-[2-(2-hydroxyethyl)-1-piperidinyl]ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)



RN 331773-75-2 CAPLUS
CN Benzanide, N-[4-[[7-[2-(2-ethyl-4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)



RN 331773-76-3 CAPLUS
CN Benzanide, N-[4-[[7-[2-(4,5-dihydro-1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]phenyl- (CA INDEX NAME)




IT 331776-59-1 331776-60-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)


RN 331776-59-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[[4-(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 331776-60-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[(benzoylamino)phenyl]amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:754870 CAPLUS
 DOCUMENT NUMBER: 134:304837
 TITLE: Inhibition of VEGF signal transduction: identification of ZD4190
 AUTHOR(S): Wedge, Stephen R.; Ogilvie, Donald J.
 CORPORATE SOURCE: Cancer and Infection Research Department, AstraZeneca Pharmaceuticals, Cheshire, SK10 4TG, UK
 SOURCE: Advances in Experimental Medicine and Biology (2000), 476(Angiogenesis: From the Molecular to Integrative Pharmacology), 307-310
 CODEN: AEMBAP; ISSN: 0065-2598
 PUBLISHER: Kluwer Academic/Plenum Publishers
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 IT 257938-36-6, ZD 4190
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (inhibition of VEGF signal transduction: identification of ZD4190)
 RN 257938-36-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:573671 CAPLUS
 DOCUMENT NUMBER: 133:177183
 TITLE: Preparation of quinazoline derivatives as angiogenesis inhibitors
 INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick;
 Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren
 PATENT ASSIGNEE(S): AstraZeneca UK Limited, UK; Zeneca-Pharma S.A.
 SOURCE: PCT Int. Appl., 346 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362715	A1	20000817	CA 2000-2362715	20000208 <--
EP 1154774	A1	20011121	EP 2000-902730	20000208 <--
EP 1154774	B1	20050622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102314	T2	20020121	TR 2001-2314	20000208 <--
BR 2000008128	A	20020213	BR 2000-8128	20000208 <--
HU 2001004964	A2	20020429	HU 2001-4964	20000208 <--
HU 2001004964	A3	20030228		
JP 2002536414	T	20021029	JP 2000-598164	20000208 <--
JP 3893026	B2	20070314		
EE 200100409	A	20021216	EE 2001-409	20000208 <--
AU 763618	B2	20030731	AU 2000-24475	20000208 <--

NZ 513204	A	20040430	NZ 2000-513204	20000208 <--
CN 1597667	A	20050323	CN 2004-10058982	20000208 <--
TR 200500745	T2	20050523	TR 2005-745	20000208 <--
NZ 530832	A	20050527	NZ 2000-530832	20000208 <--
EP 1553097	A1	20050713	EP 2005-4285	20000208 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 298237	T	20050715	AT 2000-902730	20000208 <--
RU 2262935	C2	20051027	RU 2001-124816	20000208 <--
PT 1154774	T	20051031	PT 2000-902730	20000208 <--
ES 2242596	T3	20051116	ES 2000-902730	20000208 <--
IN 2000DE00115	A	20050311	IN 2000-DE115	20000211 <--
IN 2001MN00893	A	20070525	IN 2001-MN93	20010726 <--
ZA 2001006340	A	20021101	ZA 2001-6340	20010801 <--
NO 2001003882	A	20011009	NO 2001-3882	20010809 <--
NO 321604	B1	20060612		
MX 2001PA0182	A	20030820	MX 2001-PA8182	20010810 <--
HK 1041212	A1	20051202	HK 2002-102781	20020412 <--
US 7074800	B1	20060711	US 2002-913020	20020506 <--
NO 2005002773	A	20011009	NO 2005-2773	20050608 <--
US 2006004017	A1	20060105	US 2005-169122	20050629 <--
JP 2006273860	A	20061012	JP 2006-129249	20060508 <--
KR 2008015482	A	20080219	KR 2007-731001	20071231 <--
PRIORITY APPLN. INFO.:				
		EP 1999-400305	A 19990210 <--	
		EP 2000-902730	A3 20000208 <--	
		JP 2000-598164	A3 20000208 <--	
		WO 2000-GB373	W 20000208 <--	
		KR 2001-710133	A3 20010810 <--	
		US 2002-913020	A3 20020506 <--	

OTHER SOURCE(S): MARPAT 133:177183


IT 288383-55-1P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288383-59-5P , 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(1-methylpiperidin-4-ylmethoxy)quinazoline hydrochloride 288384-25-8P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(1-methylinidazol-2-yl)ethoxy]quinazoline 288384-29-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(2-furylmethoxy)quinazoline 288384-31-6P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(pyrrolidin-1-yl)ethoxy]quinazoline 288384-33-8P, 7-[2-(5,5-Dimethyl-1,3-dioxan-2-yl)ethoxy]-4-(2,3-dimethylindol-5-ylamino)-6-methoxyquinazoline 288384-34-9P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline 288384-37-2P, 4-(2,3-Dimethylindol-5-ylamino)-6-methoxy-7-[2-(3-pyridyl)ethoxy]quinazoline 288385-44-4P, 4-(Indol-5-ylamino)-6-methoxy-7-[3-pyridyl)methoxy]quinazoline 288385-45-5P, 4-(Indol-5-ylamino)-6-methoxy-7-[2-(4-methyl-1,3-thiazol-5-yl)ethoxy]quinazoline 288385-50-2P, 6-Methoxy-4-(2-methylindol-5-ylamino)-7-(2-piperidinoethoxy)quinazoline 288385-61-5P, 4-(Indol-5-ylamino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline 288385-67-1P, 4-(Indol-6-ylamino)-6-methoxy-7-(2-piperidinoethoxy)quinazoline 288385-71-7P, 4-(Indol-6-ylamino)-6-methoxy-7-(3-pyridyl)methoxy]quinazoline 288386-50-5P, 4-(Indol-5-ylamino)-6-methoxy-7-[1-(2-methylsulfonylethyl)piperidin-4-yl)methoxy]quinazoline hydrochloride 288386-52-7P, 4-(Indol-5-ylamino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline hydrochloride 288386-58-3P, 4-(Indol-5-ylamino)-7-[2-(imidazol-1-yl)ethoxy]-6-methoxyquinazoline hydrochloride 288387-64-4P, 6-Methoxy-4-(indol-6-ylamino)-7-[2-(4-methylthiazol-5-yl)ethoxy]quinazoline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)

(angiogenesis inhibitor; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN 288383-55-1 CAPLUS


CN 4-Quinazolinamine, N-(2,3-dimethyl-1H-indol-5-yl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 288383-59-5 CAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-(2-methyl-1H-indol-5-yl)-7-[(1-methyl-4-piperidinyl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 288384-25-8 CAPLUS


CN 4-Quinazolinamine, N-(2,3-dimethyl-1H-indol-5-yl)-6-methoxy-7-[2-(1-methyl-1H-imidazol-2-yl)ethoxy]- (CA INDEX NAME)




RN 288384-29-2 CAPLUS
CN 4-Quinazolinamine, N-(2,3-dimethyl-1H-indol-5-yl)-7-(2-furanylmethoxy)-6-methoxy- (CA INDEX NAME)




RN 288384-31-6 CAPLUS
CN 4-Quinazolinamine, N-(2,3-dimethyl-1H-indol-5-yl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 288384-33-8 CAPLUS
CN 4-Quinazolinamine, 7-[2-(5,5-dimethyl-1,3-dioxan-2-yl)ethoxy]-N-(2,3-dimethyl-1H-indol-5-yl)-6-methoxy- (CA INDEX NAME)




RN 288384-34-9 CAPLUS
CN 4-Quinazolinamine, N-(2,3-dimethyl-1H-indol-5-yl)-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 288384-37-2 CAPLUS
 CN 4-Quinazolinamine, N-(2,3-dimethyl-1H-indol-5-yl)-6-methoxy-7-[2-(3-pyridinyl)ethoxy]- (CA INDEX NAME)



RN 288385-44-4 CAPLUS
 CN 4-Quinazolinamine, N-1H-indol-5-yl-6-methoxy-7-(3-pyridinylmethoxy)- (CA INDEX NAME)




RN 288385-45-5 CAPLUS
 CN 4-Quinazolinamine, N-1H-indol-5-yl-6-methoxy-7-[2-(4-methyl-5-thiazolyl)ethoxy]- (CA INDEX NAME)




RN 288385-50-2 CAPLUS

CN 4-Quinazolinamine, 6-methoxy-N-(2-methyl-1H-indol-5-yl)-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 288385-61-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-5-yl-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 288385-67-1 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-6-yl-6-methoxy-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 288385-71-7 CAPLUS

CN 4-Quinazolinamine, N-1H-indol-6-yl-6-methoxy-7-(3-pyridinylmethoxy)- (CA INDEX NAME)



RN 288386-50-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indol-5-yl-6-methoxy-7-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 288386-52-7 CAPLUS


CN 4-Quinazolinamine, N-1H-indol-5-yl-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 288386-58-3 CAPLUS

CN 4-Quinazolinamine, 7-[2-(1H-imidazol-1-yl)ethoxy]-N-1H-indol-5-yl-6-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 288387-64-4 CAPLUS
 CN 4-Quinazolinamine, N-1H-indol-6-yl-6-methoxy-7-[2-(4-methyl-5-thiazolyl)ethoxy]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:241203 CAPLUS
 DOCUMENT NUMBER: 132:265207
 TITLE: Preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease
 INVENTOR(S): Cumming, John Graham
 PATENT ASSIGNEE(S): Zeneca Limited, UK
 SOURCE: PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000020402	A1	20000413	WO 1999-GB32200	19990927 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

CA 2341374	A1	20000413	CA 1999-2341374	19990927 <--
AU 9961064	A	20000426	AU 1999-61064	19990927 <--
AU 761552	B2	20030605		
BR 9914162	A	20010626	BR 1999-14162	19990927 <--
EP 1117653	A1	20010725	EP 1999-947686	19990927 <--
EP 1117653	B1	20030205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526538	T	20020820	JP 2000-574519	19990927 <--
AT 232205	T	20030215	AT 1999-947686	19990927 <--
NZ 510210	A	20030630	NZ 1999-510210	19990927 <--
PT 1117653	T	20030630	PT 1999-947686	19990927 <--
ES 2191462	T3	20030901	ES 1999-947686	19990927 <--
ZA 200102187	A	20020618	ZA 2001-2187	20010315 <--
US 6593333	B1	20030715	US 2001-787883	20010323 <--
NO 2001001631	A	20010521	NO 2001-1631	20010330 <--
NO 318892	B1	20050518		
MX 2001PA03424	A	20010731	MX 2001-PA3424	20010402 <--
HK 1037367	A1	20030822	HK 2001-108138	20011119 <--
US 2003216417	A1	20031120	US 2003-441084	20030520 <--
US 6716847	B2	20040406		
PRIORITY APPLN. INFO.:				
			GB 1998-21338	A 19981001 <--
			GB 1999-6564	A 19990323 <--
			WO 1999-GB3220	W 19990927 <--
			US 2001-787883	A3 20010323 <--


OTHER SOURCE(S):

IT 263400-09-5P 263400-10-8P 263400-39-1P
263400-53-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-anilinoquinazolines and 4-anilinoquinolines as inhibitors of cytokine mediated disease)

RN 263400-09-5 CAPLUS


CN Acetanide, N-[2-fluoro-5-[(6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 263400-10-8 CAPLUS


CN Acetanide, N-[2-fluoro-5-[(6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]phenyl]-2-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 263400-39-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-4-quinazolinyl]amino)-4-methylphenyl]-2-(4-morpholinyl)- (CA INDEX NAME)




RN 263400-53-9 CAPLUS

CN 4-Pyridinecarboxamide, N-[3-[(6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinazolinyl]amino)-4-methylphenyl]-2-(4-morpholinyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:160214 CAPLUS
 DOCUMENT NUMBER: 132:303106
 TITLE: ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
 AUTHOR(S): Wedge, Stephen R.; Ogilvie, Donald J.; Dukes, Michael; Kendrew, Jane; Curwen, Jon O.; Hennequin, Laurent F.; Thomas, Andrew P.; Stokes, Elaine S. E.; Curry, Brenda; Richmond, Graham H. P.; Wadsworth, Peter F.
 CORPORATE SOURCE: Departments of Cancer and Infection Research, AstraZeneca Pharmaceuticals, Macclesfield, SK10 4TG, UK
 SOURCE: Cancer Research (2000), 60(4), 970-975
 CODEN: CNREA8; ISSN: 0008-5472
 PUBLISHER: AACR Subscription Office
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 257938-36-6, ZD 4190
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ZD4190: orally active inhibitor of VEGF signaling with broad-spectrum antitumor efficacy)
 RN 257938-36-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:810602 CAPLUS
 DOCUMENT NUMBER: 132:160709
 TITLE: Antiangiogenic agents
 AUTHOR(S): Klohs, Wayne D.; Hamby, James M.
 CORPORATE SOURCE: Department of Drug Development, Parke-Davis Pharmaceutical Research, Warner-Lambert Company, Ann Arbor, MI, 48105, USA

SOURCE: Current Opinion in Biotechnology (1999),
 10(6), 544-549
 CODEN: CUOBEB; ISSN: 0958-1669
 PUBLISHER: Current Biology Publications
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 IT 257938-36-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiangiogenic agents for treatment of cancer)
 RN 257938-36-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
 L4 ANSWER 41 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:784580 CAPLUS
 DOCUMENT NUMBER: 132:151769
 TITLE: Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors
 AUTHOR(S): Hennequin, Laurent F.; Thomas, Andrew P.; Johnstone, Craig; Stokes, Elaine S. E.; Ple, Patrick A.; Lohmann, Jean-Jacques M.; Ogilvie, Donald J.; Dukes, Mike; Wedge, Steve R.; Curwen, Jon O.; Kendrew, Jane; Lambert-van der Brempt, Christine
 CORPORATE SOURCE: AstraZeneca Zeneca Pharma Centre de Recherches Z.I. La Pompelle, Reims, 51689, Fr.
 SOURCE: Journal of Medicinal Chemistry (1999), 42(26), 5369-5389
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 192999-91-0P 193000-14-5P 193000-48-5P
 193000-50-9P 205193-33-5P 257938-32-2P
 257938-33-3P 257938-36-6P 257938-37-7P
 257938-38-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and structure-activity relationship of arylaminoquinazoline VEGF receptor tyrosine kinase inhibitors)

RN 192999-91-0 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 193000-14-5 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(4-pyridinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 193000-48-5 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(3-thienylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-50-9 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 205193-33-5 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 257938-32-2 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 257938-33-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 257938-36-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 257938-37-7 CAPLUS

CN 4-Quinazolinamine, N-(4-bromo-2,6-difluorophenyl)-6-methoxy-7-[2-(1H-1,2,3-triazol-1-yl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 257938-38-8 CAPLUS
 CN Benzonitrile, 3-fluoro-4-[(6-methoxy-7-{2-(1H-1,2,3-triazol-1-yl)ethoxy}-4-quinazolinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 42 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:219675 CAPLUS
 DOCUMENT NUMBER: 128:257441
 TITLE: Preparation of quinazoline derivatives and pharmaceutical compositions containing them
 INVENTOR(S): Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Johnstone, Craig; Stokes, Elaine Sophie Elizabeth; Lohmann, Jean Jacques Marcel; Clayton, Edward
 PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.; Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Johnstone, Craig; Stokes, Elaine Sophie Elizabeth; Lohmann, Jean Jacques Marcel; Clayton, Edward
 SOURCE: PCT Int. Appl., 137 pp.
 CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813354	A1	19980402	WO 1997-GB2588	19970923 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ,UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9708553	A	19980325	ZA 1997-8553	19970923 <--
CA 2263319	A1	19980402	CA 1997-2263319	19970923 <--
CA 2263319	C	20040323		
AU 9745613	A	19980417	AU 1997-45613	19970923 <--
AU 729968	B2	20010215		
EP 929530	A1	19990721	EP 1997-943954	19970923 <--
EP 929530	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9711302	A	19990817	BR 1997-11302	19970923 <--
CN 1231662	A	19991013	CN 1997-198133	19970923 <--
NZ 334014	A	20001027	NZ 1997-334014	19970923 <--
JP 2001500891	T	20010123	JP 1998-515387	19970923 <--
JP 3438818	B2	20030818		
IL 129038	A	20021110	IL 1997-129038	19970923 <--
AT 228114	T	20022125	AT 1997-943954	19970923 <--
RU 2198879	C2	20030220	RU 1999-108663	19970923 <--
SK 283175	B6	20030304	SK 1999-389	19970923 <--
PT 929530	T	20030331	PT 1997-943954	19970923 <--
ES 2185999	T3	20030501	ES 1997-943954	19970923 <--
JP 2003238539	A	20030827	JP 2003-79216	19970923 <--
PL 190326	B1	20051130	PL 1997-332385	19970923 <--
DE 69717294	C5	20060209	DE 1997-69717294	19970923 <--
CZ 296962	B6	20060816	CZ 1999-1039	19970923 <--
TW 520364	B	20030211	TW 1997-86113896	19970924 <--
IN 1997D02733	A	20050311	IN 1997-DE2733	19970924 <--
NO 9901422	A	19990324	NO 1999-1422	19990324 <--
NO 313138	B1	20020819		
KR 2000048572	A	20000725	KR 1999-702499	19990324 <--
US 6414148	B1	20020702	US 1999-269595	19990325 <--
HK 1019332	A1	20030905	HK 1999-104114	19990922 <--
US 2002173646	A1	20021121	US 2002-80716	20020225 <--
US 6673803	B2	20040106		
JP 2004002406	A	20040108	JP 2003-120734	20030320 <--
US 2004242574	A1	20041202	US 2003-698388	20031103 <--
US 6897210	B2	20050524		
US 2005239777	A1	20051027	US 2004-24840	20041230 <--
PRIORITY APPLN. INFO.:			EP 1996-402033	A 19960925 <--
			EP 1997-401042	A 19970509 <--
			JP 1998-515387	A3 19970923 <--
			WO 1997-GB2588	W 19970923 <--
			US 1999-269595	A3 19990325 <--
			US 2002-80716	A1 20020225 <--
			US 2003-698388	A1 20031103


OTHER SOURCE(S): MARPAT 128:257441
IT 205193-32-4P 205193-33-5P 205193-36-8P

205193-42-6P 205193-43-7P 205193-44-8P
205193-45-9P 205193-53-9P 205193-65-3P
205193-68-6P 205193-69-7P 205193-70-0P
205193-71-1P 205193-82-4P 205193-92-6P
205193-97-1P 205193-98-2P 205194-02-1P
205194-39-4P 205194-43-0P 205194-48-5P
205194-56-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as antitumor, antiangiogenic and antiarthritic agents)


RN 205193-32-4 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(1,3-dioxolan-2-yl)ethoxy]-6-methoxy- (CA INDEX NAME)




RN 205193-33-5 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 205193-36-8 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-(1,3-dioxolan-2-ylmethoxy)-6-methoxy- (CA INDEX NAME)




RN 205193-42-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-thiomorpholinyl)ethoxy]- (CA INDEX NAME)




RN 205193-43-7 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 205193-44-8 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 205193-45-9 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(1-methyl-3-piperidinyl)methoxy]- (CA INDEX NAME)




RN 205193-53-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 205193-65-3 CAPLUS
CN 2,6-Piperidinedione, 1-[2-[(4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl]- (CA INDEX NAME)



RN 205193-68-6 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(tetrahydro-3-furanyl)methoxy]- (CA INDEX NAME)




RN 205193-69-7 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[(4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl]-, monohydrochloride (HCl) (CA INDEX NAME)




● HCl


RN 205193-70-0 CAPLUS
CN 2-Imidazolidinone, 1-[2-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl]- (CA INDEX NAME)



RN 205193-71-1 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(1,1-dioxido-4-thiomorpholinyl)ethoxy]-6-methoxy- (CA INDEX NAME)




RN 205193-82-4 CAPLUS
CN 3-Morpholinone, 4-[2-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 205193-92-6 CAPLUS
CN Piperazine, 1-acetyl-4-[2-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 205193-97-1 CAPLUS
CN 3-Morpholinone, 4-[2-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 205193-98-2 CAPLUS


CN 2-Pyrrolidinone, 1-[2-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 205194-02-1 CAPLUS


CN 3,5-Morpholinedione, 4-[[2-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 205194-39-4 CAPLUS

CN 2-Pyrrolidinone, 1-[2-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl- (CA INDEX NAME)




RN 205194-43-0 CAPLUS


CN 3-Morpholinone, 4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl- (CA INDEX NAME)



RN 205194-48-5 CAPLUS
CN 3-Morpholininone, 4-[2-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl - (CA INDEX NAME)



RN 205194-56-5 CAPLUS
CN 2-Pyrrolidinone, 1-[2-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl - (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 43 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:675952 CAPLUS
DOCUMENT NUMBER: 127:262698
TITLE: Preparation of quinazolines as VEGF inhibitors
INVENTOR(S): Thomas, Andrew Peter; Johnstone, Craig; Hennequin, Laurent Francois Andre
PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.; Thomas, Andrew Peter; Johnstone, Craig; Hennequin, Laurent Francois Andre
SOURCE: PCT Int. Appl., 102 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 9730035	A1	19970821	WO 1997-GB365	19970210 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2242425	A1	19970821	CA 1997-2242425	19970210 <--
CA 2242425	C	20060718		
AU 9717290	A	19970902	AU 1997-17290	19970210 <--
AU 719434	B2	20000511		
EP 880508	A1	19981202	EP 1997-904512	19970210 <--
EP 880508	B1	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1211239	A	19990317	CN 1997-192221	19970210 <--
CN 1125817	B	20031029		
BR 9707495	A	19990727	BR 1997-7495	19970210 <--
NZ 330868	A	20000128	NZ 1997-330868	19970210 <--
JP 2000504714	T	20000418	JP 1997-529078	19970210 <--
IL 125686	A	20021110	IL 1997-125686	19970210 <--
RU 2196137	C2	20030110	RU 1998-117074	19970210 <--
CZ 291386	B6	20030212	CZ 1998-2535	19970210 <--
AT 237596	T	20030515	AT 1997-904512	19970210 <--
PT 880508	T	20030731	PT 1997-904512	19970210 <--
ES 2194181	T3	20031116	ES 1997-904512	19970210 <--
SK 285141	B6	20060707	SK 1998-1087	19970210 <--
PL 194689	B1	20070629	PL 1997-328310	19970210 <--
ZA 9701180	A	19970813	ZA 1997-1180	19970212 <--
TW 581765	B	20040401	TW 1997-86101670	19970212 <--
NO 9803687	A	19980813	NO 1998-3687	19980812 <--
NO 311359	B1	20011119		
US 6184225	B1	20010206	US 1998-125271	19980813 <--
HK 1016607	A1	20030926	HK 1999-101774	19990421 <--
PRIORITY APPLN. INFO.:			EP 1996-400293	A 19960213 <--
			EP 1996-401756	A 19960808 <--
			EP 1996-402764	A 19961217 <--
			WO 1997-GB365	W 19970210 <--


OTHER SOURCE(S): MARPAT 127:262698

IT 196194-05-5P	196194-06-6P	196194-07-7P	
196194-08-8P	196194-18-0P	196194-25-9P	
196194-27-1P	196194-35-1P		
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of quinazolines as VEGF inhibitors)			
RN 196194-05-5	CAPLUS		
CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino)-, dihydrochloride (9CI) (CA INDEX NAME)			




●2 HCl

RN 196194-06-6 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 196194-07-7 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 196194-08-8 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(1-piperidinyl)ethoxy]-4-


quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 196194-18-0 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(4-thiomorpholinyl)ethoxy]-4-quinazolinyl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 196194-25-9 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(1-pyrrolidinyl)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 196194-27-1 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(1-piperidinyl)ethoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 196194-35-1 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(4-thiomorpholinyl)ethoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)



L4 ANSWER 44 OF 46 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:640511 CAPLUS
 DOCUMENT NUMBER: 127:278209
 TITLE: Preparation of 4-anilinoquinazolines for use in the treatment of disease states associated with

antiangiogenesis and/or increased vascular
permeability

INVENTOR(S): Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Johnstone, Craig

PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.; Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Johnstone, Craig

SOURCE: PCT Int. Appl., 72 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732856	A1	19970912	WO 1997-GB550	19970228 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9701747	A	19980827	ZA 1997-1747	19970227 <--
CA 2244897	A1	19970912	CA 1997-2244897	19970228 <--
CA 2244897	C	20060411		
AU 9718664	A	19970922	AU 1997-18664	19970228 <--
AU 719327	B2	20000504		
EP 885198	A1	19981223	EP 1997-906814	19970228 <--
EP 885198	B1	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1212684	A	19990331	CN 1997-192807	19970228 <--
CN 1116286	B	20030730		
NZ 331191	A	20000327	NZ 1997-331191	19970228 <--
JP 2000517291	T	20001226	JP 1997-531552	19970228 <--
AT 211134	T	20020115	AT 1997-906814	19970228 <--
PT 885198	T	20020628	PT 1997-906814	19970228 <--
ES 2169355	T3	20020701	ES 1997-906814	19970228 <--
IL 125954	A	20030624	IL 1997-125954	19970228 <--
IN 1997DE00542	A	20050311	IN 1997-DE542	19970303 <--
TW 542826	B	20030721	TW 1997-86102593	19970304 <--
NO 9804085	A	19980904	NO 1998-4085	19980904 <--
NO 311427	B1	20011126		
US 6291455	B1	20010918	US 1998-142339	19980908 <--
PRIORITY APPLN. INFO.:			EP 1996-400468	A 19960305 <--
			EP 1996-401499	A 19960708 <--
			WO 1997-GB550	W 19970228 <--


OTHER SOURCE(S): MARPAT 127:278209

IT 196603-50-6P 196603-60-8P 196603-67-5P
 196603-68-6P 196603-72-2P 196603-76-6P
 196603-77-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-anilinoquinazolines for use in the treatment of disease states associated with antiangiogenesis and/or increased vascular permeability)


RN 196603-50-6 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 196603-60-8 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)




RN 196603-67-5 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-, hydrochloride (10:27) (CA INDEX NAME)




●27/10 HCl

RN 196603-68-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 196603-72-2 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 196603-76-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 196603-77-7 CAPLUS
 CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



TITLE: Preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivatives
 INVENTOR(S): Lohmann, Jean-Jacques Marcel; Hennequin, Laurent Francois Andre; Thomas, Andrew Peter
 PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma S.A.; Lohmann, Jean-Jacques Marcel; Hennequin, Laurent Francois Andre; Thomas, Andrew Peter
 SOURCE: PCT Int. Appl., 162 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9722596	A1	19970626	WO 1996-GB3075	19961213 <--
W: AL, AM, AT, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN	AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2237005	A1	19970626	CA 1996-2237005	19961213 <--
CA 2237005	C	20060314		
AU 9711061	A	19970714	AU 1997-11061	19961213 <--
AU 712370	B2	19991104		
EP 873319	A1	199881028	EP 1996-941787	19961213 <--
EP 873319	B1	20010725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1205694	A	19990120	CN 1996-199110	19961213 <--
CN 1133625	B	20040107		
HU 9901243	A2	19990830	HU 1999-1243	19961213 <--
HU 9901243	A3	20011128		
BR 9612043	A	19991228	BR 1996-12043	19961213 <--
JP 20000515114	T	20001114	JP 1997-522568	19961213 <--
AT 203524	T	20010815	AT 1996-941787	19961213 <--
ES 2162656	T3	20020101	ES 1996-941787	19961213 <--
PT 873319	T	20020130	PT 1996-941787	19961213 <--
SK 282443	B6	20020205	SK 1998-828	19961213 <--
CZ 291100	B6	20021211	CZ 1998-1882	19961213 <--
RU 2194701	C2	20021220	RU 1998-113300	19961213 <--
PL 192309	B1	20060929	PL 1996-327310	19961213 <--
ZA 9610597	A	19970618	ZA 1996-10597	19961217 <--
US 5962458	A	19991005	US 1996-768887	19961217 <--
TW 411274	B	20001111	TW 1996-85115569	19961217 <--
IN 1996DE02844	A	20050311	IN 1996-DE2844	19961217 <--
NO 9802784	A	19980817	NO 1998-2784	19980617 <--
NO 311358	B1	20011119		
US 6071921	A	20000606	US 1998-203764	19981202 <--
US 6258951	B1	20010710	US 2000-500470	20000209 <--
US 2002032208	A1	20020314	US 2001-877005	20010611 <--
US 6362336	B2	20020326		
GR 3036954	T3	20020131	GR 2001-401823	20011019 <--
PRIORITY APPLN. INFO.:			EP 1995-402846	A 19951218 <--
			EP 1996-402190	A 19961015 <--
			EP 1996-941787	A 19961213 <--
			WO 1996-GB3075	W 19961213 <--
			US 1996-768887	A1 19961217 <--

US 1998-203764
US 2000-500470

A1 19981202 <--
A3 20000209 <--


OTHER SOURCE(S): MARPAT 127:135808
IT 192999-68-1P 192999-69-2P 192999-70-5P
192999-71-6P 192999-72-7P 192999-73-8P
192999-74-9P 192999-75-0P 192999-76-1P
192999-77-2P 192999-80-7P 192999-85-2P
192999-87-4P 192999-89-6P 192999-91-0P
192999-92-1P 192999-93-2P 192999-94-3P
192999-95-4P 192999-99-8P 193000-00-9P
193000-01-0P 193000-02-1P 193000-04-3P
193000-05-4P 193000-06-5P 193000-07-6P
193000-08-7P 193000-09-8P 193000-10-1P
193000-14-5P 193000-18-9P 193000-26-9P
193000-27-0P 193000-28-1P 193000-29-2P
193000-30-5P 193000-31-6P 193000-32-7P
193000-42-9P 193000-44-1P 193000-45-2P
193000-46-3P 193000-47-4P 193000-48-5P
193000-49-6P 193000-50-9P 193000-55-4P
193000-56-5P 193000-57-6P 193000-58-7P
193000-59-8P 193000-60-1P 193000-62-3P
193000-63-4P 193000-64-5P 193000-66-7P
193000-67-8P 193000-68-9P 193000-70-3P
193000-71-4P 193000-72-5P 193000-73-6P
193000-75-8P 193000-76-9P 193000-77-0P
193000-78-1P 193000-79-2P 193000-80-5P
193000-83-8P 193000-85-0P 193000-87-2P
193000-88-3P 193000-91-8P 193000-92-9P
193000-93-0P 193000-94-1P 193000-95-2P
193000-96-3P 193000-97-4P 193000-98-5P
193001-00-2P 193001-03-5P 193001-04-6P
193001-06-8P 193001-18-2P 193001-20-6P
193001-26-2P 193001-28-4P 193001-30-8P
193001-32-0P 193001-35-3P 193001-38-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation and antiangiogenic and/or vascular permeability reducing effect of quinazoline derivs.)

RN 192999-68-1 CAPLUS


CN Phenol, 5-[(6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (5:1) (CA INDEX NAME)




RN 192999-69-2 CAPLUS
CN Phenol, 5-[(6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)



RN 192999-70-5 CAPLUS
CN Phenol, 5-[(6-methoxy-7-(3-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)




RN 192999-71-6 CAPLUS
CN Phenol, 5-[(6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-methyl-, hydrochloride (4:3) (CA INDEX NAME)



● 3/4 HCl


RN 192999-72-7 CAPLUS

CN Phenol, 5-[6-methoxy-7-(4-pyrimidinylmethoxy)-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)



RN 192999-73-8 CAPLUS


CN Phenol, 5-[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (CA INDEX NAME)



●19/10 HCl

RN 192999-74-9 CAPLUS


CN Phenol, 5-[(6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl)amino]-2-methyl-, hydrochloride (10:17) (CA INDEX NAME)



●17/10 HCl

RN 192999-75-0 CAPLUS


CN Phenol, 5-[(6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-76-1 CAPLUS


CN Acetamide, N-[4-[(4-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●₂ HCl


RN 192999-77-2 CAPLUS

CN Phenol, 5-[(7-[(3,5-dimethyl-4-isoxazolyl)methoxy]-6-methoxy-4-quinazolinyl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192999-80-7 CAPLUS
 CN Phenol, 4-fluoro-5-[(6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl)amino]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 192999-85-2 CAPLUS
 CN 2(1H)-Pyridinone, 1-[2-[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 192999-87-4 CAPLUS


CN 4(1H)-Pyridinone, 1-[2-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxyethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-89-6 CAPLUS


CN Phenol, 4-fluoro-5-[(6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quiazolinyl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 192999-91-0 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 192999-92-1 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-, hydrochloride (2:3) (CA INDEX NAME)




● 3/2 HCl

RN 192999-93-2 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 192999-94-3 CAPLUS
CN Phenol, 4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl]amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192999-95-4 CAPLUS
 CN Acetanide, N-[4-[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl]oxymethyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 192999-99-8 CAPLUS
 CN Phenol, 4-fluoro-5-[[7-(2-(1H-imidazol-1-yl)ethoxy)-6-methoxy-4-quinazolinyl]amino]-2-methyl-, hydrochloride (10:19) (CA INDEX NAME)




●19/10 HCl

RN 193000-00-9 CAPLUS
CN Phenol, 2-chloro-4-fluoro-5-[(7-{2-(1H-imidazol-1-yl)ethoxy}-6-methoxy-4-quinazolinyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 193000-01-0 CAPLUS
CN Phenol, 4-fluoro-5-[(6-methoxy-7-{2-(4-pyridinyl)ethoxy}-4-quinazolinyl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-02-1 CAPLUS
CN Phenol, 4-fluoro-5-[(6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-04-3 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-pyridinyl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 193000-05-4 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(3-pyridinylmethoxy)-, hydrochloride (5:8) (CA INDEX NAME)




●8/5 HCl

RN 193000-06-5 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(2-pyridinylmethoxy)- (CA INDEX NAME)



RN 193000-07-6 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1-methyl-1H-imidazol-2-yl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 193000-08-7 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(4-pyrimidinylmethoxy)-, hydrochloride (10:19) (CA INDEX NAME)




● 19/10 HCl

RN 193000-09-8 CAPLUS
 CN Phenol, 5-[(6-methoxy-7-[(1-methyl-1H-benzimidazol-2-yl)methoxy]-4-quinazolinyl)amino]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-10-1 CAPLUS
 CN Phenol, 5-[(7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl)amino]-4-fluoro-2-methyl-, hydrochloride (10:19) (CA INDEX NAME)




● 19/10 HCl

RN 193000-14-5 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(4-pyridinylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 193000-18-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(2-methyl-1H-imidazol-1-yl)ethoxy]-, hydrochloride (10:21) (CA INDEX NAME)



● 21/10 HCl

RN 193000-26-9 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-27-0 CAPLUS


CN Phenol, 5-[(7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl)amino]-4-fluoro-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-28-1 CAPLUS

CN 4-Quinazolinamine, 7-[{(2-bromo-4-pyridinyl)methoxy]-N-(4-chloro-2-fluorophenyl)- (CA INDEX NAME)




RN 193000-29-2 CAPLUS

CN 2-Pyridinecarbonitrile, 4-[[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]- (CA INDEX NAME)



RN 193000-30-5 CAPLUS


CN 2(1H)-Pyridinone, 6-chloro-4-[[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-31-6 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(2-methoxy-4-pyridinyl)methoxy]- (CA INDEX NAME)




RN 193000-32-7 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(2-methyl-4-pyridinyl)methoxy]- (CA INDEX NAME)



RN 193000-42-9 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]quinazolin-2-yl]amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193000-44-1 CAPLUS


CN Phenol, 4-fluoro-5-[(6-methoxy-7-{[2-(1H-1,2,4-triazol-1-yl)ethoxy]-4-quinazolinyl}amino)-2-methyl-, hydrochloride (5:6) (CA INDEX NAME)



● 6/5 HCl

RN 193000-45-2 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl]amino-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193000-46-3 CAPLUS


CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl)amino]-, hydrochloride (5:9) (CA INDEX NAME)



● 9/5 HCl


RN 193000-47-4 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl)amino]-, hydrochloride (5:6) (CA INDEX NAME)




● 6/5 HCl

RN 193000-48-5 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(3-thienylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193000-49-6 CAPLUS
 CN Acetamide, N-[4-[[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-2-thiazolyl]-, hydrochloride (10:11) (CA INDEX NAME)




● 11/10 HCl

RN 193000-50-9 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl

RN 193000-55-4 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(3,5-dimethyl-4H-1,2,4-triazolo-4-yl)ethoxy]-6-methoxy-, hydrochloride (10:19) (CA INDEX NAME)




●19/10 HCl

RN 193000-56-5 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(2,4-dimethyl-1H-imidazol-1-yl)ethoxy]-6-methoxy-, hydrochloride (10:19) (CA INDEX NAME)




●19/10 HCl

RN 193000-57-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(3-pyridinyl)ethoxy]-, hydrochloride (5:9) (CA INDEX NAME)




● 9/5 HCl

RN 193000-58-7 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(6-methyl-2-pyridinyl)ethoxy]-, hydrochloride (5:9) (CA INDEX NAME)




● 9/5 HCl

RN 193000-59-8 CAPLUS
 CN Phenol, 3-[[7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-, hydrochloride (10:19) (CA INDEX NAME)




● 19/10 HCl

RN 193000-60-1 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4H-1,2,4-triazol-4-yl)ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 193000-62-3 CAPLUS
 CN 2-Pyridinecarboxylic acid, 4-[[[4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl]-, ethyl ester (CA INDEX NAME)



RN 193000-63-4 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(2-(methylamino)-4-pyridinyl)methoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193000-64-5 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[(2-(dimethylamino)-4-pyridinyl)methoxy]-6-methoxy-, trihydrochloride (9CI) (CA INDEX NAME)




• 3 HCl

RN 193000-66-7 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]-, hydrochloride (10:19) (CA INDEX NAME)




● 19/10 HCl


RN 193000-67-8 CAPLUS
CN 4(1H)-Pyridinone, 1-[2-[(4-[(4-chloro-2-fluorophenyl)amino]-6-methoxy-7-quinazolinyl]oxy)ethyl]- (CA INDEX NAME)




RN 193000-68-9 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy- (CA INDEX NAME)




RN 193000-70-3 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4-pyridinyl)ethoxy]- (CA INDEX NAME)




RN 193000-71-4 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(4-pyridinylmethoxy)- (CA INDEX NAME)




RN 193000-72-5 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(2-methyl-1H-imidazol-1-yl)ethoxy]- (CA INDEX NAME)




RN 193000-73-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1H-1,2,4-triazol-1-yl)ethoxy]- (CA INDEX NAME)




RN 193000-75-8 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1-methyl-1H-imidazol-2-yl)ethoxy]- (CA INDEX NAME)




RN 193000-76-9 CAPLUS
 CN Phenol, 5-[(6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-77-0 CAPLUS
 CN Phenol, 5-[(6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-78-1 CAPLUS
 CN Phenol, 5-[(6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-79-2 CAPLUS
 CN Phenol, 4-[(6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)



RN 193000-80-5 CAPLUS
 CN Acetamide, N-[4-[(4-[(3-hydroxy-4-methylphenyl)amino]-6-methoxy-7-quinazolinyl)oxy]methyl]-2-thiazolyl- (CA INDEX NAME)




RN 193000-83-8 CAPLUS
 CN Phenol, 4-fluoro-5-[(6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-85-0 CAPLUS

CN Phenol, 4-fluoro-5-[(6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-87-2 CAPLUS

CN Phenol, 4-fluoro-5-[(6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-88-3 CAPLUS


CN Acetamide, N-[4-[[4-[(2-fluoro-5-hydroxy-4-methylphenyl)amino]oxy]methyl]-2-thiazolyl]- (CA INDEX NAME)




RN 193000-91-8 CAPLUS
 CN Phenol, 4-fluoro-5-[(7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)




RN 193000-92-9 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 193000-93-0 CAPLUS
 CN Phenol, 4-fluoro-5-[(6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-94-1 CAPLUS
 CN Phenol, 4-fluoro-5-[(6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-95-2 CAPLUS
 CN Phenol, 5-[(6-methoxy-7-[(1-methyl-1H-benzimidazol-2-yl)methoxy]-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193000-96-3 CAPLUS
 CN Phenol, 5-[(7-[(2-chloro-6-methyl-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl)amino]-4-fluoro-2-methyl- (CA INDEX NAME)




RN 193000-97-4 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 193000-98-5 CAPLUS
 CN Phenol, 5-[(7-[(2-chloro-4-pyridinyl)methoxy]-6-methoxy-4-quinazolinyl)amino]-4-fluoro-2-methyl- (CA INDEX NAME)




RN 193001-00-2 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 193001-03-5 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 193001-04-6 CAPLUS

CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[2-(4-pyridinyl)ethoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)




RN 193001-06-8 CAPLUS


CN Phenol, 5-[(6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl)amino]-2-methyl- (CA INDEX NAME)




RN 193001-18-2 CAPLUS
 CN Phenol, 2-chloro-4-fluoro-5-[(6-methoxy-7-[(2-methyl-4-thiazolyl)methoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 193001-20-6 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-(3-thienylmethoxy)- (CA INDEX NAME)




RN 193001-26-2 CAPLUS
 CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)ethoxy]-6-methoxy- (CA INDEX NAME)




RN 193001-28-4 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(2,4-dimethyl-1H-imidazol-1-yl)ethoxy]-6-methoxy- (CA INDEX NAME)



RN 193001-30-8 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(2,5-dimethyl-1H-imidazol-1-yl)ethoxy]-6-methoxy- (CA INDEX NAME)



RN 193001-32-0 CAPLUS


CN Phenol, 3-[(7-[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl]amino)-

(CA INDEX NAME)




RN 193001-35-3 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(4H-1,2,4-triazol-4-yl)ethoxy]- (CA INDEX NAME)




RN 193001-38-6 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-2-fluorophenyl)-7-[2-(2,5-dimethyl-1H-imidazol-1-yl)ethoxy]-6-methoxy-, hydrochloride (10:19) (CA INDEX NAME)




●19/10 HCl


IT 193001-43-3P 193001-46-6P 193001-47-7P
 193001-48-8P 193001-49-9P 193001-50-2P
 193001-71-7P 193001-72-8P 193001-75-1P
 193001-76-2P 193001-77-3P 193001-78-4P
 193002-15-2P 193002-17-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and antiangiogenic and/or vascular permeability reducing effect
 of quinazoline derivs.)
 RN 193001-43-3 CAPLUS
 CN Phenol, 5-[(6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]amino]-2-
 methyl-, acetate (ester) (9CI) (CA INDEX NAME)



RN 193001-46-6 CAPLUS
 CN Phenol, 5-[(6-methoxy-7-(2-pyridinylmethoxy)-4-quinazolinyl]amino]-2-
 methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 193001-47-7 CAPLUS
 CN Phenol, 5-[(6-methoxy-7-(4-pyrimidinylmethoxy)-4-quinazolinyl]amino]-2-
 methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 193001-48-8 CAPLUS

CN Phenol, 5-[(6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl)amino]-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 193001-49-9 CAPLUS

CN Acetamide, N-[4-[(4-acetoxyphenyl)amino]-6-methoxy-7-quinazolinyl]oxy]methyl- (CA INDEX NAME)




RN 193001-50-2 CAPLUS

CN Phenol, 5-[(7-(3,5-dimethyl-4-isoxazolyl)methoxy)-6-methoxy-4-quinazolinyl]amino]-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 193001-71-7 CAPLUS

CN Carbonic acid, 4-fluoro-5-[(7-{[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy-4-quinazolinyl}amino)-2-methylphenyl methyl ester (CA INDEX NAME)




RN 193001-72-8 CAPLUS

CN 4-Quinazolinamine, N-[4-chloro-5-[(1,1-dimethylethyl)diphenylsilyl]oxy]-2-fluorophenyl]-7-{[2-(1H-imidazol-1-yl)ethoxy]-6-methoxy- (CA INDEX NAME)




RN 193001-75-1 CAPLUS

CN Carbonic acid, 4-fluoro-5-[(6-methoxy-7-{[2-(4-pyridinyl)ethoxy]-4-quinazolinyl}amino)-2-methylphenyl methyl ester (CA INDEX NAME)




RN 193001-76-2 CAPLUS

CN Carbonic acid, 4-fluoro-5-[(6-methoxy-7-(3-thienylmethoxy)-4-quinazolinyl)amino]-2-methylphenyl methyl ester (CA INDEX NAME)




RN 193001-77-3 CAPLUS

CN Phenol, 5-[(6-methoxy-7-[(1-methyl-1H-benzimidazol-2-yl)methoxy]-4-quinazolinyl)amino]-2-methyl-, acetate (ester) (9CI) (CA INDEX NAME)




RN 193001-78-4 CAPLUS

CN Carbonic acid, 5-[(7-[(2-chloro-6-methyl-4-pyridinyl)ethoxy]-6-methoxy-4-quinazolinyl)amino]-4-fluoro-2-methylphenyl methyl ester (9CI) (CA INDEX NAME)




RN 193002-15-2 CAPLUS

CN 4-Quinazolinamine, N-[4-chloro-5-[(1,1-dimethylethyl)diphenylsilyloxy]-2-fluorophenyl]-6-methoxy-7-[(1-methyl-1H-imidazol-2-yl)methoxy]- (CA INDEX NAME)



RN 193002-17-4 CAPLUS


CN 4-Quinazolinamine, N-[4-chloro-5-[(1,1-dimethylethyl)diphenylsilyloxy]-2-fluorophenyl]-6-methoxy-7-(3-thienylmethoxy)- (CA INDEX NAME)



DOCUMENT NUMBER: 120:217715
 TITLE: Quinazoline tyrosine kinase-inhibiting anticancer agents
 INVENTOR(S): Barker, Andrew J.
 PATENT ASSIGNEE(S): Zeneca Ltd., UK
 SOURCE: Can. Pat. Appl., 99 pp.
 CODEN: CPXKEB
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2086968	A1	19930721	CA 1993-2086968	19930108 <--
CA 2086968	C	19980623		
ZA 9300015	A	19930720	ZA 1993-15	19930104 <--
AU 9331010	A	19930722	AU 1993-31010	19930104 <--
AU 661533	B2	19950727		
HU 63153	A2	19930728	HU 1993-94	19930115 <--
HU 2216222	B1	20021228		
EP 566226	A1	19931020	EP 1993-300270	19930115 <--
EP 566226	B1	19951108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE AT 130000	T	19951115	AT 1993-300270	19930115 <--
ES 2078798	T3	19951216	ES 1993-300270	19930115 <--
CZ 282038	B6	19970416	CZ 1993-43	19930118 <--
NO 9300178	A	19930721	NO 1993-178	19930119 <--
NO 301541	B1	19971110		
RU 2127263	C1	19990310	RU 1993-4423	19930119 <--
SK 281551	B6	20010510	SK 1993-16	19930119 <--
FI 111631	B1	20030829	FI 1993-208	19930119 <--
KR 229294	B1	19991101	KR 1993-645	19930120 <--
IL 104479	A	19991222	IL 1993-104479	19930121 <--
JP 06073025	A	19940315	JP 1993-26577	19930216 <--
JP 2994165	B2	19991227		
US 5457105	A	19951010	US 1994-284293	19940802 <--
US 5616582	A	19970401	US 1995-490666	19950615 <--
PRIORITY APPLN. INFO.:			GB 1992-1095	A 19920120 <--
			GB 1992-13572	A 19920626 <--
			GB 1992-23735	A 19921112 <--
			US 1993-5280	B1 19930119 <--
			US 1994-284293	A1 19940802 <--

OTHER SOURCE(S): MARPAT 120:217715
 IT 153437-22-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of, as tyrosine kinase-inhibiting anticancer agent)
 RN 153437-22-0 CAPLUS
 CN 4-Quinazolinamine, 6-methoxy-N-(3-methylphenyl)-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



=>
=> log hold
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE	TOTAL
	ENTRY	SESSION
201.42		380.87

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:41:36 ON 24 MAR 2008